Prescription Medicines
Dapazin-S duo Tab. 10/100mg
- Product Category
- Diabetes treatment
- Active Ingredients
- Dapagliflozin, sitagliptin
- Appearance
- A white, oblong, film-coated tablet.
- Reimbursement Code
- 648104910
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredients:
Dapagliflozin Bis L-Proline (in-house specification) ----- 15.63mg (10mg as dapagliflozin)
Sitagliptin phosphate monohydrate (USP) ----- 128.48mg (100mg as sitagliptin)
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: Anhydrous calcium hydrogen phosphate, microcrystalline cellulose, magnesium stearate, Opadry white (03B28796), low-substituted hydroxypropyl cellulose, carnauba lead, colloidal silicon oxide, croscarmellose sodium, hydroxypropyl cellulose, D-mannitol
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve glycemic control in patients with type 2 diabetes who are suitable for combined administration of sitagliptin and dapagliflozin.
3. Dosage and dosage
This drug can be administered 1 tablet once a day, regardless of meal, to patients taking 100 mg of sitagliptin and 10 mg of dapagliflozin. Tablets should be swallowed whole.
special group
Patients with renal impairment
The effectiveness and safety of this drug depend on renal function, and it is recommended to periodically evaluate renal function before and after administration of this drug.
- If the estimated glomerular filtration rate (eGFR) is more than 45mL/min/1.73m2, dose adjustment is not necessary.
- Do not administer this drug if the estimated glomerular filtration rate (eGFR) is less than 45mL/min/1.73m2.
Hepatic impairment patients
No dose adjustment is necessary for patients with mild or moderate hepatic impairment. The use of this drug is not recommended for patients with severe hepatic impairment.
4. Precautions for use
1. Warning
1) Sitagliptin
(1) Hypersensitivity reaction
Severe hypersensitivity reactions have been reported in patients receiving post-marketing sitagliptin, including anaphylaxis, angioedema, and exfoliative skin disorders, including Stevens-Johnson syndrome. Because they are voluntarily reported from an unspecified population, it is generally not possible to reliably estimate their incidence or establish a causal relationship with drug exposure. The onset of this reaction occurred within the first 3 months of drug treatment and has also been reported after the first dose. If hypersensitivity reaction is suspected, discontinue this drug, evaluate other potential reasons for the occurrence, and implement other diabetes treatment (see 2. Do not administer to the following patients and 4. Adverse reactions, 2) Sitagliptin, (2) Post-marketing adverse reactions).
(2) Pancreatitis
Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis, has been reported in patients treated with sitagliptin (see section 4. Adverse reactions, 2) Sitagliptin). After starting treatment with this drug, carefully observe whether symptoms of pancreatitis appear. If pancreatitis is suspected, administration of this drug and other suspected drugs should be discontinued.
2. Do not administer to the following patients
1) Patients with a history of hypersensitivity to the main ingredients or excipients of this drug (including anaphylaxis or angioedema (see 1. Warning section))
2) Patients with type 1 diabetes or diabetic ketoacidosis
3) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
4) Patients on dialysis
3. Administer with caution to the following patients:
1) Dapagliflozin
(1) Administration in patients with decreased body fluid volume and renal dysfunction
Dapagliflozin may cause a decrease in intravascular blood volume, which may manifest as symptomatic hypotension or sudden and temporary changes in creatinine. In foreign post-marketing surveillance, acute kidney injury was reported in patients receiving SGLT-2 inhibitors, including dapagliflozin, and some required hospitalization and dialysis. The risk of hypovolemia or hypotension may increase in patients with renal dysfunction (eGFR less than 60mL/min/1.73m2), the elderly, and those using loop diuretics. For patients with these characteristics, it is necessary to evaluate body fluid status and renal function before starting dapagliflozin administration, and after starting administration, monitor symptoms and signs of hypotension and renal function.
The glucose-lowering efficacy of dapagliflozin depends on renal function. Efficacy is reduced in patients with moderate renal impairment, and dapagliflozin is not recommended solely for glycemic control in patients with type 2 diabetes and an eGFR below 45 mL/min/1.73 m². Among patients with moderate renal impairment, elevated creatinine, phosphorus and parathyroid hormone (PTH) levels and hypotension were reported more frequently with dapagliflozin than with placebo.
2) Sitagliptin
(1) Patients with renal impairment: Sitagliptin is excreted through the kidneys. To achieve blood levels similar to those in patients with normal renal function, lower doses are recommended in patients with a glomerular filtration rate [eGFR] <45 mL/min/1.73 m2 and in patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis.
4. Adverse reactions
1) Dapagliflozin
(1) Summary of safety profile
In clinical studies of patients with type 2 diabetes, more than 15,000 patients received dapagliflozin.
Safety and tolerability were assessed through a predefined pooled analysis of 13 short-term (up to 24 weeks) placebo-controlled trials involving 2,360 patients administered 10 mg of dapagliflozin and 2,295 patients administered placebo.
In the clinical trial to evaluate the cardiovascular effects of dapagliflozin in patients with type 2 diabetes (DECLARE), 8,574 people were administered dapagliflozin 10 mg and 8,569 people were administered placebo, and the median exposure period was 48 months. There were a total of 30,623 patient-years of dapagliflozin exposure.
The most commonly reported adverse reactions throughout clinical studies were genital infections.
(2) List of adverse reactions
The following adverse reactions were observed in placebo-controlled clinical trials. There were no dose-related adverse reactions. The adverse reactions listed below are classified according to frequency and organ system (SOC). Frequency of presentation was defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), and unknown (cannot be assessed from available data).
Table 1 Adverse events in placebo-controlled trials? See documentation -
(3) Description of specific adverse reactions
① Vulvovaginitis, balanitis and related genital infections
Pooled safety data from 13 clinical trials showed that vulvovaginitis, balanitis, and related genital infections were reported in 5.5% and 0.6% of subjects receiving dapagliflozin 10 mg and placebo, respectively. Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women (8.4% and 1.2% in the dapagliflozin and placebo groups, respectively), and subjects with a prior medical history were more likely to have recurrent infections.
In the DECLARE clinical trial, the number of serious adverse events of genital infection was very small and evenly distributed (2 patients each in the dapagliflozin and placebo groups).
In the DAPA-HF clinical trial, no serious adverse events of genital infection were reported in the dapagliflozin group and one case was reported in the placebo group. There were 7 patients (0.3%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection.
In the DAPA-CKD clinical trial, serious adverse events of genital infection were reported in 3 cases (0.1%) in the dapagliflozin group and none in the placebo group. There were 3 patients (0.1%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection. In patients without diabetes, no serious adverse events of genital infection or adverse events leading to discontinuation of treatment were reported.
② Low blood sugar
The frequency of hypoglycemia in clinical trials in patients with diabetes depended on the type of baseline therapy used in each trial.
In additional combination studies of dapagliflozin administered alone, metformin, or sitagliptin (metformin alone or in combination), the frequency of mild hypoglycemic episodes was similar (<5%) between treatment groups, including placebo, up to 102 weeks of treatment. In a comprehensive analysis of safety information from 1,169 patients evaluated for dapagliflozin and saxagliptin combination therapy, the overall incidence of hypoglycemia was low at 24 weeks (≤1.8% in all groups).
In all trials, major hypoglycemic events were uncommon and equivalent between dapagliflozin and placebo groups. The incidence of hypoglycemia was higher in studies with the addition of sulfonylurea and in studies with the addition of insulin.
In the glimepiride add-on study, mild hypoglycemic episodes were reported more frequently at weeks 24 and 48 in those receiving dapagliflozin 10 mg and glimepiride (6.0% and 7.9%, respectively) compared to those receiving placebo and glimepiride (2.1% and 2.1%, respectively).
In the insulin add-on combination study, major hypoglycemic episodes were reported in 0.5% and 1.0% of patients receiving dapagliflozin 10 mg in combination with insulin at weeks 24 and 104, respectively, and in patients receiving placebo in combination with insulin, major hypoglycemic episodes were reported in 0.5% of cases at weeks 24 and 104. Mild hypoglycemic episodes were reported in 40.3% and 53.1% of patients receiving dapagliflozin 10 mg in combination with insulin at weeks 24 and 104, respectively, and in 34.0% and 41.6% of patients receiving placebo in combination with insulin.
In an add-on therapy trial of metformin and sulfonylureas, no major episodes of hypoglycemia were reported by week 24. Mild hypoglycemic episodes were reported in 12.8% of subjects receiving dapagliflozin 10 mg plus metformin and sulfonylurea and 3.7% of subjects receiving placebo plus metformin and sulfonylurea.
The DECLARE trial showed that dapagliflozin therapy compared with placebo did not increase the risk of major hypoglycemic events. Major hypoglycemic events were reported in 58 patients (0.7%) in the dapagliflozin group and 83 patients (1.0%) in the placebo group.
In the DAPA-HF clinical trial, major hypoglycemic events were reported in 4 patients (0.2%) each in the dapagliflozin and placebo groups, and occurred only in patients with type 2 diabetes.
In the DAPA-CKD clinical trial, major hypoglycemic events were reported in 14 patients (0.7%) in the dapagliflozin group and 28 patients (1.3%) in the placebo group, and were observed only in patients with type 2 diabetes.
③ Reduction in body fluid volume
According to pooled safety data from 13 clinical trials, drug reactions suggestive of volume loss (including dehydration, hypovolemia, or hypotension) were reported in 1.1% and 0.7% of subjects receiving dapagliflozin 10 mg and placebo, respectively; Serious reactions, occurring in less than 0.2% of subjects, were evenly distributed between the dapagliflozin 10 mg and placebo groups.
In the DECLARE clinical trial, the number of patients who developed adverse events suggesting a decrease in body fluid volume was evenly distributed among treatment groups: 213 (2.5%) in the dapagliflozin group and 207 (2.4%) in the placebo group. Serious adverse events were reported in 81 patients (0.9%) in the dapagliflozin group and 70 patients (0.8%) in the placebo group. Adverse events were generally evenly distributed between treatment groups across subgroups, including age, use of diuretics, blood pressure, and use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In the patient population with a baseline estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m2, 19 serious adverse events suggesting volume loss were reported in the dapagliflozin group and 13 cases in the placebo group.
In the DAPA-HF clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 170 (7.2%) in the dapagliflozin group and 153 (6.5%) in the placebo group. The number of patients with serious adverse events suggesting volume loss was lower in the dapagliflozin group (23 [1.0%]) than in the placebo group (38 [1.6%]). Similar results were observed across subgroups including age, presence of diabetes at baseline, baseline eGFR, and systolic blood pressure.
In the DAPA-CKD clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 120 (5.6%) in the dapagliflozin group and 84 (3.9%) in the placebo group. The number of patients with serious adverse events suggesting a decrease in body fluid volume was 16 (0.7%) in the dapagliflozin group and 15 (0.7%) in the placebo group.
④ Diabetic ketoacidosis
In the DECLARE clinical trial (median dapagliflozin exposure period of 48 months), 27 cases of diabetic ketoacidosis were reported in the patient group administered dapagliflozin 10 mg and 12 cases in the placebo group. Occurrence points were evenly distributed throughout the study period. Of the 27 patients who developed diabetic ketoacidosis in the dapagliflozin group, 22 were taking insulin at the time the case occurred. Factors causing diabetic ketoacidosis appeared as expected in the type 2 diabetes patient population (see ‘4. General precautions, 3) Ketoacidosis’).
In the DAPA-HF clinical trial, diabetic ketoacidosis cases were reported in 3 patients with type 2 diabetes in the dapagliflozin group and no cases in the placebo group.
In the DAPA-CKD clinical trial, no cases of diabetic ketoacidosis were reported in the dapagliflozin group and two cases of type 2 diabetes were reported in the placebo group.
⑤ Urinary tract infection
Pooled safety data from 13 clinical trials showed that urinary tract infections were reported more frequently in the dapagliflozin 10 mg group compared to the placebo group (4.7% vs 3.5%, respectively). Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women, and subjects with a previous medical history were more likely to develop recurrent infections.
In the DECLARE clinical trial, 79 cases (0.9%) of serious adverse events of urinary tract infection were reported in the dapagliflozin 10 mg treatment group, which was less frequent than the 109 cases (1.3%) in the placebo group.
In the DAPA-HF clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was small, with no significant difference between the two groups: 14 patients (0.6%) in the dapagliflozin group and 17 patients (0.7%) in the placebo group. There were 5 patients (0.2%) in each of the dapagliflozin and placebo groups who discontinued treatment due to adverse events of urinary tract infection.
In the DAPA-CKD clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was 29 (1.3%) in the dapagliflozin group and 18 (0.8%) in the placebo group. There were 8 patients (0.4%) in the dapagliflozin group and 3 (0.1%) in the placebo group who discontinued treatment due to adverse events of urinary tract infection.
⑥ Increased creatinine
Adverse reactions associated with increased creatinine were classified as decreased renal creatinine clearance, renal impairment, increased blood creatinine, and decreased glomerular filtration rate. According to pooled safety data from 13 clinical trials, these adverse reactions were reported in 3.2% and 1.8% of subjects receiving dapagliflozin 10 mg and placebo, respectively. In normal subjects or patients with mild renal failure (eGFR 60 mL/min/1.73 m2 or higher), these adverse reactions were reported in 1.3% and 0.8% of patients receiving dapagliflozin 10 mg and placebo, respectively. These adverse reactions were reported more frequently in patients with an eGFR greater than 30 mL/min/1.73 m2 but less than 60 mL/min/1.73 m2 (18.5% and 9.3% for dapagliflozin 10 mg and placebo, respectively).
In the subsequent evaluation of patients with kidney-related adverse events, changes in serum creatinine of ≤ 0.5 mg/dL from baseline were observed in most patients. Increased creatinine usually occurs transiently during treatment or resolves after treatment is discontinued.
In the DECLARE clinical trial, which included elderly patients and patients with renal impairment (eGFR less than 60 mL/min/1.73m2), eGFR decreased over time in both the dapagliflozin group and the placebo group. After 1 year, the average eGFR was slightly lower in the dapagliflozin group, and after 4 years, the average eGFR in the dapagliflozin group was slightly higher than the placebo group.
In the DAPA-HF clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial decrease in mean eGFR was -4.3 mL/min/1.73 m2 in the dapagliflozin group and -1.1 mL/min/1.73 m2 in the placebo group. At 20 months, the change from baseline in eGFR was similar between treatment groups (dapagliflozin group -5.3 mL/min/1.73 m2, placebo group -4.5 mL/min/1.73 m2).
In the DAPA-CKD clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial (day 14) decrease in average eGFR was -4.0 mL/min/1.73 m2 in the dapagliflozin group and -0.8 mL/min/1.73 m2 in the placebo group. The change from baseline in eGFR at 28 months was -7.4 mL/min/1.73 m2 in the dapagliflozin group and -8.6 mL/min/1.73 m2 in the placebo group.
⑦ Perineal gangrene (Fournier’s gangrene)
During post-marketing surveillance, cases of Fournier's gangrene have been reported in patients receiving SGLT2 inhibitors, including dapagliflozin (see 4. General precautions, 12) Perineal gangrene (Fournier's gangrene).
In the DECLARE clinical trial involving 17,160 patients with type 2 diabetes and a median exposure period of 48 months, a total of 6 cases of Fournier's gangrene were reported, including 1 case in the dapagliflozin group and 5 cases in the placebo group.
(4) Post-marketing surveillance
The following are additional adverse drug reactions confirmed after the marketing of dapagliflozin. This adverse drug reaction was reported voluntarily from an uncharacteristic large population, so it is not possible to reliably predict its incidence.
- Ketoacidosis (including diabetic ketoacidosis)
- Urosepsis and pyelonephritis
- Acute kidney injury and renal dysfunction
- Rash: Rash includes the following representative terms in order of frequency in clinical studies: rash, generalized rash, pruritic rash, macular rash, maculopapular rash, pustular rash, bullous rash, and erythematous rash. In active-controlled and placebo-controlled clinical studies (5,936 people in the dapagliflozin group, 3,403 people in all control groups), the frequency of rash was similar in the dapagliflozin group (1.4%) and all control groups (1.4%) and was ‘common.’
(5) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,027 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 26.59% (805/3,027 people, total 1,122 cases) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence. - Refer to manual -
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence. - Refer to manual -
2) Sitagliptin
(1) Clinical trials
① Because clinical trials are conducted under wide and diverse conditions, the incidence of adverse reactions observed in clinical trials cannot be directly compared to the rates in clinical trials of other drugs, and cannot reflect the rates observed under actual use environments.
In clinical trials of sitagliptin, when sitagliptin was administered as monotherapy or combination therapy (metformin or pioglitazone or rosiglitazone and metformin), the incidence of adverse reactions and hypoglycemia was generally similar to that reported for placebo. Cases where treatment was discontinued due to adverse reactions were similar to those in the placebo group.
During glimepiride or glimepiride and metformin combination therapy, the frequency of adverse reactions in the sitagliptin group was higher than the placebo group (Table 4). This is partly due to the high incidence of hypoglycemia in the sitagliptin administration group. Discontinuation of treatment due to adverse reactions was similar to that in the placebo group.
Two placebo-controlled monotherapy studies conducted for 18 and 24 weeks included groups receiving sitagliptin 100 mg and 200 mg daily and placebo. Five additional placebo-controlled combination therapy studies administered 100 mg of sitagliptin or placebo daily in combination with stable doses of metformin, pioglitazone, rosiglitazone, and metformin, glimepiride (±metformin), or insulin (±metformin), respectively.
In these clinical trials, except for hypoglycemia and regardless of causality assessment, adverse reactions reported at a frequency of 5% or more among patients taking sitagliptin 100 mg daily for 18 weeks and more frequently than placebo are listed in Table 2. The frequency of occurrence of hypoglycemia is shown in Table 4.
Table 2. Placebo-controlled clinical trials with sitagliptin monotherapy or combination therapy (pioglitazone, or rosiglitazone and metformin, or glimepiride (±metformin)): Adverse reactions excluding hypoglycemia, which were reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment - see description -
In patients who received sitagliptin and metformin in combination for 24 weeks, there were no adverse reactions reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment.
In patients who received sitagliptin in combination with a stable dose of insulin (±metformin) for 24 weeks, there were no adverse reactions except hypoglycemia, which was reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment (see Table 4 for hypoglycemia). In patients receiving additional sitagliptin during another 24-week insulin intensification period (±metformin), the adverse reaction reported at a frequency greater than 5% and more frequently than placebo, regardless of causality assessment, was diarrhea (5.2% for this drug; 3.3% for placebo).
In patients who received sitagliptin in combination with rosiglitazone and metformin for 54 weeks, adverse reactions reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment, were: upper respiratory tract infection (sitagliptin 15.5%, placebo 6.2%), nasopharyngitis (11.0%, 9.3%), peripheral edema (8.3%, 5.2%), and Headache (5.5%, 4.1%).
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the occurrence of specific gastrointestinal adverse reactions in patients treated with sitagliptin was as follows: abdominal pain (sitagliptin 100 mg 2.3%, placebo 2.1%), nausea (sitagliptin 100 mg 1.4%, placebo 0.6%), Diarrhea (sitagliptin 100mg 3.0%, placebo 2.3%)
In a placebo-controlled factorial design clinical trial conducted for 24 weeks, adverse reactions reported at a frequency of 5% or more or more frequently than placebo, regardless of causality assessment, upon initial co-administration of sitagliptin and metformin are shown in Table 3.
Table 3. Initial combination therapy of sitagliptin and metformin: Adverse reactions reported at a frequency of more than 5% and more frequently than sitagliptin alone, metformin alone, and placebo, regardless of causality assessment? See documentation -
No clinically significant changes in vital signs or ECG (including QTc interval) were observed with sitagliptin administration.
② Pancreatitis
When the results of 19 double-blind clinical trials of 10,246 patients randomly assigned to sitagliptin 100 mg/day (N=5429) or the corresponding control group (active comparator or placebo) (N=4817) were pooled and analyzed, the incidence of acute pancreatitis in each group was 0.1 per 100 patient-years (in the sitagliptin group) reported in 4 patients out of 4708 patient-years and in the control group in 4 patients out of 3942 patient-years). In the TECOS cardiovascular safety trial, the incidence of acute pancreatitis was reported to be 0.11 (23/7,332, 25 cases) per 100 patient-years in the sitagliptin group and 0.06 (12/7,339, 17 cases) per 100 patient-years in the placebo group. (See 1. Warning, 1) Sitagliptin, (2) Pancreatitis section, and TECOS Cardiovascular Safety Clinical Trial section)
③ TECOS cardiovascular safety clinical trial (TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin)
The intent-to-treat (ITT) group of the cardiovascular safety clinical trial of sitagliptin included 7,332 patients who received sitagliptin 100 mg daily (or 50 mg daily if eGFR≥30 and <50 mL/min/1.73 m2 at baseline) and 7,339 patients who received placebo. In this trial, sitagliptin or placebo was administered in addition to usual treatment in each country related to HbA1c and cardiovascular (CV) risk factors. Sitagliptin administration did not increase the risk of hospitalization due to major cardiovascular disease or heart failure. The reported incidence of serious adverse reactions was similar at 12.7% in the sitagliptin group and 12.4% in the placebo group.
Severe hypoglycemia was reported in 2.2% of the sitagliptin group (160 patients; 0.78 per 100 patient-years) and 1.9% of the placebo group (143 patients; 0.70 per 100 patient-years). Among patients receiving insulin and/or a sulfonylurea, the incidence was 2.7% with sitagliptin (138/5,021 patients) and 2.5% with placebo (125/4,931 patients). Among patients not receiving insulin or a sulfonylurea, the incidence was 1.0% with sitagliptin (22/2,311 patients) and 0.7% with placebo (18/2,408 patients). Confirmed acute pancreatitis occurred in 0.3% of the sitagliptin group and 0.2% of the placebo group.
④ Low blood sugar
In all studies (9), hypoglycemic adverse events were based on reports of symptomatic hypoglycemia. Although blood sugar measurement was not necessarily required, most reports of hypoglycemia (74%) were below 70 mg/dL when measured. When sitagliptin was administered in combination with a sulfonylurea or insulin, the proportion of patients with one or more hypoglycemic adverse events was higher than in the placebo group (see Table 4).
Table 4. Placebo-controlled trials of sitagliptin in combination with glimepiride (±metformin) or insulin (±metformin): Incidence of reported hypoglycemia, regardless of causality assessment? See documentation -
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the incidence of hypoglycemia as an adverse reaction in patients administered sitagliptin 100 mg was similar to that of placebo (1.2% for sitagliptin 100 mg, 0.9% for placebo).
In a clinical trial of the combination therapy of sitagliptin, rosiglitazone, and metformin, the incidence of hypoglycemia up to 18 weeks was 2.2% in the sitagliptin group and 0.0% in the placebo group. The incidence up to 54 weeks was 3.9% and 1.0%, respectively.
In a placebo-controlled factorial trial conducted for 24 weeks, the incidence of hypoglycemia during initial co-administration of sitagliptin and metformin was 0.6% in the placebo group, 0.6% in the sitagliptin-only group, 0.8% in the metformin-only group, and 1.6% in the sitagliptin-metformin combination group.
⑤ Laboratory tests
The incidence of laboratory adverse reactions in the group administered 100 mg of sitagliptin was 8.2%, and in the group administered placebo it was 9.8%. In clinical trials, a slight increase in white blood cell count due to an increase in neutrophils (about 200 cells/μL difference compared to placebo administration; average baseline value of about 6600 cells/μL) was observed. This difference has been shown in many, but not all, studies, and changes in laboratory values are not believed to be clinically relevant.
In a 12-week study, 91 patients with chronic renal impairment and 37 patients with moderate renal impairment were randomly assigned to sitagliptin 50 mg, and 14 patients with the same degree of renal impairment were randomized to placebo. The mean (standard error) increase in serum creatinine was 0.12 mg/dL (0.04) in the sitagliptin group and 0.07 mg/dL (0.07) in the placebo group. The clinical significance of increased serum creatinine compared to placebo is unknown.
⑥ Domestic clinical trial results
The safety and efficacy of sitagliptin were evaluated in a bridging clinical trial conducted in 530 Asians in a multinational, double-blind, randomized, placebo-controlled, parallel group study, of which 95 were Korean. The safety profile of sitagliptin in Koreans was overall similar to that of placebo and did not show significant differences from the results reported in previous clinical trials.
(2) Post-marketing adverse reactions
The following are additional adverse reactions confirmed after the marketing of sitagliptin. Because these adverse reactions are voluntarily reported from an unspecified population, it is generally not possible to reliably predict their frequency or establish a causal relationship with drug exposure. Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, cutaneous angiitis and exfoliative skin diseases including Stevens-Johnson syndrome (see section 1. Warnings), elevated liver enzymes; Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis (see 1. Warning, 1) Sitagliptin, (2) Pancreatitis); Deterioration of renal function, including acute renal failure (sometimes requiring dialysis); upper respiratory tract infection; nasopharyngitis; constipation; puke; headache; Severe and disabling arthralgia (see sections 5. General precautions, 2) Sitagliptin, (2) Severe and disabling arthralgia); Bullous pemphigoid (see section 5. General precautions, 2) Sitagliptin, (3) Bullous pemphigoid); myalgia; Pain in limbs; back pain; interstitial lung disease; pruritus; It is thrombocytopenia. During post-marketing use, rhabdomyolysis was reported when taken with statin drugs. (Domestic clue information analysis and evaluation results)
(3) Domestic post-marketing survey results
① As a result of a use result survey conducted on 3,453 people over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 4.87% (168/3,453 people) [232 cases] regardless of causal relationship, and among these, the incidence of adverse drug reactions for which a causal relationship with sitagliptin could not be ruled out was 1.56% (54/3,453 people). [64 cases] ‘hypoglycemia’ at 0.26% (9 people/3,453 people) [9 cases], ‘indigestion’ and ‘dizziness’ at 0.12% each (4/3,453 people) [4 cases], ‘increased ALT’, ‘AST increase’, ‘diarrhea’, ‘nausea’, and ‘headache’ at 0.09% each (3/3,453 people) [3 cases], etc. It has been reported.
Serious adverse events were 0.12% (4/3,453 people) [5 cases] regardless of causal relationship, with ‘pneumonia’, ‘diabetic complications’, ‘metabolic acidosis’, ‘fall’, and ‘cardiac arrest’ occurring at 0.03% (1/3,453 people) [1 case] each. Among these, the serious adverse drug reaction was ‘diabetic complications’ at 0.03%. (1/3,453 people)[1 case] reported.
Unexpected adverse events were reported at 3.04% (105/3,453 people) [137 cases] regardless of causal relationship, ‘indigestion’ at 0.32% (11/3,453 people) [12 cases], ‘dizziness’ at 0.23% (8/3,453 people) [8 cases], ‘increased blood triglyceride’, and ‘gastritis’. 0.17% (6/3,453 people) [6 cases] were reported, and among these, unexpected adverse drug reactions for which a causal relationship with sitagliptin cannot be ruled out were 0.93% (32/3,453 people) [35 cases], ‘indigestion’ and ‘dizziness’ at 0.12% (4/3,453 people) [4 cases] respectively, ‘increased blood triglycerides’, ‘Increased low-density lipoprotein’ and ‘hyperglycemia’ were reported in the order of 0.06% (2/3,453 people) [2 cases] each.
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for sitagliptin with the adverse event reporting data reported for all domestically approved drugs at the end of re-examination, the following are newly identified adverse events that were statistically significantly more reported for sitagliptin than those reported for all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
· Gastrointestinal disorders: indigestion, gastritis
· Metabolic and nutritional diseases: weight loss
· Common cardiovascular diseases: high blood pressure
· Metabolic and nutritional diseases: hypernatremia
· Mental illness: erectile dysfunction
5. General precautions
1) Dapagliflozin
(1) Use for patients with hepatic impairment
Clinical trial experience in patients with hepatic impairment is limited. Dapagliflozin exposure is increased in patients with severe hepatic impairment.
(2) Use in patients at risk of volume loss and/or hypotension
Due to the mechanism of action of dapagliflozin, an increase in urination leading to a slight decrease in blood pressure was observed in clinical studies. This may be more noticeable in patients with very high blood sugar levels.
Caution should be exercised in patients who may be at risk for drug-induced reductions in blood pressure, such as patients receiving antihypertensive treatment and a history of hypotension or elderly patients.
If there are comorbidities that may cause volume loss (e.g., gastrointestinal disease), close monitoring of fluid volume status (e.g., physical examination, blood pressure measurement, and laboratory tests including hematocrit and electrolyte testing) is recommended. For patients exhibiting volume loss, temporary discontinuation of dapagliflozin is recommended until volume loss is restored.
(3) Ketoacidosis
Reports of serious, life-threatening ketoacidosis requiring prompt hospitalization have been identified in patients with type 1 and type 2 diabetes treated with SGLT2 inhibitors, including dapagliflozin. Fatal cases of ketoacidosis have been reported in patients treated with dapagliflozin.
Dapagliflozin-associated ketoacidosis may occur even when blood glucose is below 250 mg/dL. Patients treated with dapagliflozin who show signs and symptoms consistent with severe metabolic acidosis should therefore be evaluated for ketoacidosis regardless of their blood glucose level. If ketoacidosis is suspected, discontinue dapagliflozin, assess the patient’s condition and initiate treatment promptly.
Treatment of ketoacidosis may require insulin, fluid, and carbohydrate replacement.
In many post-marketing reports, particularly in patients with type 1 diabetes, the presence or absence of ketoacidosis was not immediately identified and the introduction of treatment was delayed because the observed blood glucose levels were lower than those typically expected for diabetic ketoacidosis (most often less than 250 mg/dL). Diabetes and ketoacidosis may persist longer than is generally expected, and urinary glucose secretion may persist for up to 3 days after discontinuation of treatment. However, there have been post-marketing reports that diabetes and ketoacidosis persisted for more than 6 days and up to 2 weeks after discontinuation of SGLT2 inhibitor treatment.
Symptoms and signs of ketoacidosis are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, decreased appetite, abdominal pain, malaise, and difficulty breathing. Some reports have identified factors predisposing to ketoacidosis to include reduced insulin dose, acute febrile illness, restricted calorie intake due to illness or surgery, ketogenic diet, pancreatic disorders causing insulin deficiency (e.g., type 1 and 2 diabetes, pancreatitis, or history of pancreatic surgery), and alcohol abuse.
Before starting dapagliflozin treatment, factors that may predispose to ketoacidosis, including decreased insulin secretion, calorie restriction, and alcohol abuse, should be considered. Monitor patients treated with dapagliflozin for the development of ketoacidosis, and consider temporarily discontinuing dapagliflozin administration if clinical situations predisposing to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery) occur.
Inform patients about the risk of diabetic ketoacidosis, its risk factors, signs and symptoms, and the fact that it may occur even when blood glucose is below 250 mg/dL. It is recommended that patients be able to monitor blood ketones and receive education on when monitoring is needed. Patients should seek prompt treatment if ketoacidosis is suspected.
(4) Urosepsis and pyelonephritis
Serious urinary tract infections, including urosepsis and pyelonephritis, have been reported post-marketing in patients using dapagliflozin and other SGLT2 inhibitors. SGLT2 inhibitor therapy increases the risk of urinary tract infections. If necessary, evaluate the patient's signs and symptoms of urinary tract infection and promptly treat them.
(5) Reproductive infections (including fungi)
Dapagliflozin increases the risk of genital infections (including fungal). Patients with a history of genital infections (including fungal) are more likely to develop genital infections (including fungal). Observe and treat appropriately.
(6) Elderly patients
Elderly patients are more likely to have renal impairment or be taking antihypertensive drugs that can cause changes in renal function, such as angiotensin-converting enzyme inhibitors (ACE-I) and type 1 angiotensin II receptor inhibitors (ARBs). The same recommendations regarding renal function apply to elderly patients as to all patients.
Elderly patients may be at higher risk for volume loss and are more likely to be taking diuretics.
From a pharmacokinetic perspective, there are insufficient data to make conclusions regarding blood drug exposure in patients over 70 years of age.
(7) Urine laboratory evaluation
Patients receiving dapagliflozin will test positive for urinary glucose due to its mechanism of action.
(8) Use of drugs known to cause hypoglycemia
Insulin secretagogues such as insulin and sulfonylureas cause hypoglycemia. Therefore, when used in combination with dapagliflozin, the dose of insulin or insulin secretagogue may need to be reduced to reduce the risk of hypoglycemia.
(9) SGLT2 inhibitors such as dapagliflozin may theoretically worsen the condition of patients with underlying bladder diseases that may affect urinary function by increasing urine output. Therefore, caution is required when prescribing SGLT2 inhibitors such as dapagliflozin to these patients.
(10) Weight loss
In a 24-week, placebo-controlled study of dapagliflozin monotherapy in patients with inadequately controlled type 2 diabetes, the change in body weight from baseline was −3.16 kg with dapagliflozin and −2.19 kg with placebo, indicating greater weight loss with dapagliflozin.
(11) Lower extremity amputation
In long-term clinical studies of other SGLT2 inhibitors in patients with type 2 diabetes, an increase in lower extremity amputations (mainly toes) was observed. It has not been confirmed whether this case applies to the entire series. It is important to discuss routine preventive foot care with patients with diabetes.
(12) Perineal gangrene (Fournier’s gangrene)
In post-marketing surveillance of diabetic patients taking SGLT2 inhibitors, rare cases of serious, life-threatening perineal gangrene requiring prompt surgical intervention were reported [4. Adverse reactions, 1) Dapagliflozin, (3) Description of specific adverse reactions, ⑦ Perineal gangrene (Fournier gangrene). Perineal gangrene has been reported in both men and women, resulting in hospitalization, multiple surgeries, and death.
If a patient receiving dapagliflozin develops pain, soreness, erythema, or swelling around the genitals or perineum along with fever and discomfort, perineal gangrene should be checked. If perineal gangrene is suspected, broad-spectrum antibiotic treatment should be started immediately and surgical resection should be performed if necessary. Administration of dapagliflozin should be discontinued, blood sugar levels should be closely monitored, and appropriate alternative treatment should be implemented to control blood sugar.
2) Sitagliptin
(1) Co-administration with drugs known to cause hypoglycemia: As is typical for co-administration with other hypoglycemic agents, hypoglycemia was observed when sitagliptin was co-administered with insulin or sulfonylurea (see section 4. Adverse reactions, 2) Sitagliptin). To reduce the risk of sulfonylurea- or insulin-induced hypoglycemia, a dose reduction of sulfonylureas or insulin may be considered.
(2) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
(3) Bullous pemphigoid
In post-marketing surveillance in patients taking DPP-4 inhibitors, cases of bullous pemphigus requiring hospitalization have been reported. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be informed to immediately report to their doctor if blisters or sores occur while taking sitagliptin. If bullous pemphigus is suspected, sitagliptin should be discontinued and the patient should be referred to a dermatologist for diagnosis and appropriate treatment.
6. Interaction
1) Dapagliflozin
(1) Pharmacodynamic interaction
① Diuretics: Dapagliflozin may increase the diuretic effect of thiazides and loop diuretics and may increase the risk of dehydration and hypotension.
② Insulin and insulin secretion stimulants: Insulin secretion stimulants such as insulin and sulfonylurea can cause hypoglycemia. Therefore, to reduce the risk of hypoglycemia when administered in combination with dapagliflozin, the dose of insulin or insulin secretagogue may need to be reduced.
2) Pharmacokinetic interactions
① The metabolism of dapagliflozin is mainly accomplished through glucuronide conjugation mediated by UDP-glucuronidase 1A9 (UGT1A9).
② In laboratory (in-vitro) studies, dapagliflozin did not inhibit cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, or induce CYP1A2, CYP2B6, or CYP3A4. Therefore, dapagliflozin is not expected to alter the metabolic excretion of drugs metabolized by these enzymes when coadministered with these drugs.
(3) Effects of other medicines on dapagliflozin
① As a result of an interaction study conducted on healthy subjects mainly using a single-dose design, the pharmacokinetics of dapagliflozin were not changed by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
② After co-administering dapagliflozin with rifampicin (an inducer of various active transporters and drug-metabolizing enzymes), a 22% decrease in dapagliflozin systemic exposure (AUC) was observed, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended. Clinically relevant effects are not expected with other inducers (e.g., carbamazepine, phenytoin, phenobarbital).
③ After co-administering dapagliflozin with mefenamic acid (an inhibitor of UGT1A9), systemic exposure to dapagliflozin increased by 55%, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended.
(4) Effect of dapagliflozin on other medicines
Dapagliflozin may increase renal excretion of lithium and decrease blood lithium concentrations. Serum lithium concentrations should be monitored more frequently upon initiation of dapagliflozin and after dose changes. Refer the patient to the doctor who prescribed lithium to monitor serum lithium levels.
In interaction studies conducted in healthy subjects, primarily using a single-dose design, dapagliflozin had an anticoagulant effect on the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P-gp substrate), or warfarin (S-warfarin, a CYP2C9 substrate), or the anticoagulant activity of warfarin as assessed by INR. didn't change A single co-administration of dapagliflozin 20 mg and simvastatin (CYP3A4 substrate) resulted in a 19% increase in simvastatin AUC and a 31% increase in simvastatin acid AUC. Elevated simvastatin and simvastatin acid exposure are not considered clinically relevant.
(5) Other interactions
The effects of smoking, diet, herbal medicines and alcohol on the pharmacokinetics of dapagliflozin have not been studied.
(6) Pediatrics
Interaction studies were conducted only in adults.
(7) Interference with 1,5-anhydroglucitol test
The 1,5-anhydroglucitol test is not recommended as a blood sugar control monitoring test in patients taking SGLT2 inhibitors because the reliability of the measurement results is low. Different methods are used to monitor blood sugar control.
2) Sitagliptin
In drug interaction studies, sitagliptin did not have a clinically significant effect on the pharmacokinetics of the following drugs: metformin, rosiglitazone, glibenclamide, simvastatin, warfarin, and oral contraceptives. Based on this test, it is not expected to act on substrates of CYP3A4, CYP2C8, CYP2C9 and organic cation transporters.
Co-administration of metformin and sitagliptin taken twice daily in patients with type 2 diabetes does not significantly change the pharmacokinetics of sitagliptin.
Cyclosporine: When administered as a single dose in combination with 600 mg of cyclosporine, a strong p-glycoprotein inhibitor, the AUC (29%) and Cmax (68%) of sitagliptin increased, but the change in the pharmacokinetics of sitagliptin is not expected to be clinically significant. No significant interaction is expected when coadministered with cyclosporine or other p-glycoprotein inhibitors.
Digoxin: When coadministered with 100 mg of sitagliptin for 10 days, the plasma AUC (11%) and Cmax (18%) of digoxin slightly increased. Appropriate monitoring should be conducted when administering digoxin, and dose adjustment of sitagliptin and digoxin is not necessary.
7. Administration to pregnant and lactating women
1) Pregnant women
(1) Dapagliflozin: There is no data on the administration of dapagliflozin to pregnant women. Studies on rats showed toxicity to kidney development during the second and third trimesters of human pregnancy. The use of dapagliflozin in pregnant women is not recommended. Once pregnancy is confirmed, dapagliflozin administration should be discontinued.
The effects of dapagliflozin on human fertility have not been studied. In male and female rats, dapagliflozin showed no effects on fertility at any of the doses studied.
(2) Sitagliptin: There are no controlled test results in pregnant women, so its use in pregnant women is not recommended.
2) Nursing mothers
(1) Dapagliflozin: It is not known whether dapagliflozin and its metabolites are transferred into human milk. Pharmacodynamic/toxicological data in animals indicate excretion of dapagliflozin/metabolite in milk and pharmacologically mediated effects in nursing offspring. Risk to neonates/infants cannot be excluded. Dapagliflozin should not be used during breastfeeding.
(2) Sitagliptin: Sitagliptin is reported to be secreted into milk and plasma at a ratio of 4:1 in rats, so it is not administered to nursing mothers.
8. Administration to children
The safety and efficacy of dapagliflozin in pediatric patients have not been established.
9. Administration to elderly people
1) Sitagliptin
Of the total subjects (3,884) in the pre-approval clinical trial, 725 were over 65 years of age and 61 were over 75 years of age. Safety and efficacy in elderly patients aged 65 years or older were similar to those in younger patients. Although there was no difference in responsiveness between this patient group and the younger patient group, it cannot be ruled out that susceptibility may be increased in some elderly patients.
Sitagliptin is known to be largely excreted by the kidneys. Elderly people are prone to decreased kidney function, so care must be taken when selecting the dose in the elderly, and it is recommended to periodically evaluate kidney function before and after administration of sitagliptin.
10. Treatment in case of overdose
1) Dapagliflozin
Dapagliflozin did not show any toxicity at single oral doses of up to 500 mg (50 times the maximum recommended human dose) in healthy subjects. These subjects had detectable urinary glucose throughout the treatment period (more than 5 days for the 500 mg dose), no dehydration, hypotension, or electrolyte imbalances were reported, and there were no clinically significant effects on the QTc interval. The incidence of hypoglycemia was similar to placebo. In a clinical trial in which healthy subjects and patients with type 2 diabetes were administered up to 100 mg (10 times the maximum recommended human dose) once daily for 2 weeks, the incidence of hypoglycemia was slightly higher than in the placebo group and was not dose-related. Rates of adverse events, including dehydration or hypotension, were similar to the placebo group, and there were no clinically meaningful dose-related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function.
If overdose occurs, appropriate symptomatic treatment should be administered according to the patient's clinical condition. Elimination of dapagliflozin by dialysis has not been studied.
2) Sitagliptin
In clinical trials of sitagliptin, a single dose of up to 800 mg of sitagliptin was administered to healthy adults. In one study administering 800 mg of sitagliptin, an increase in mean QTc of up to 8.0 msec was observed, but this is not believed to be clinically relevant. There is no experience administering doses exceeding 800 mg in humans.
In case of overdose, general symptomatic treatment is administered (e.g., removal of unabsorbed drug from the gastrointestinal tract and clinical monitoring including electrocardiogram), and auxiliary treatment is provided depending on the patient's condition.
Sitagliptin can be partially removed by dialysis. In clinical trials, approximately 13.5% of the administered dose was removed during hemodialysis over 3 to 4 hours. Long-term hemodialysis should be considered if clinically appropriate. It is not known whether sitagliptin is removed by peritoneal dialysis.
11. Precautions for application
Dapagliflozin has no or little effect on the ability to drive or use machines. Patients should be aware of the risk of hypoglycemia when administering dapagliflozin in combination with sulfonylurea or insulin.
12. Precautions for storage and handling
1) Store out of reach of children.
2) It is not advisable to change the container as it may damage the quality of the product or cause an accident. Store in original container.
13. Information for experts
1) Pharmacological action
This drug is a combination of sitagliptin and dapagliflozin for the purpose of improving blood sugar control. Sitagliptin enhances glucose-mediated insulin secretion by selectively inhibiting dipeptidyl peptidase-4 (DPP-4) (incretin effect). Dapagliflozin is a selective inhibitor of sodium glucose cotransporter-2 (SGLT-2), which inhibits glucose reabsorption in the kidney independent of insulin. For both drugs, the action is regulated by blood glucose levels.
2) Pharmacokinetic information
One biopharmaceutical test was conducted to compare and evaluate the bioavailability of this drug (dapagliflozin bisL-proline/sitagliptin phosphate hydrate combination) with the combined administration of approved drugs (dapagliflozin propanediol hydrate single agent and sitagliptin phosphate hydrate single agent). This drug, which is the test drug, and the reference drug, Farxi Tablet 10 mg (dapagliflozin propanediol hydrate) [AstraZeneca Korea Co., Ltd.] and Januvia Tablet 100 mg (sitagliptin phosphate hydrate) [Korea MSD Co., Ltd.], were administered orally once on an empty stomach to healthy adults in a 2 As a result of measuring sitagliptin, when the comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, demonstrating biological equivalence.
3) Clinical trial information
In a study comparing the additional use of dapagliflozin with placebo in patients with type 2 diabetes who had insufficient glycemic control with sitagliptin alone or sitagliptin and metformin in combination, the dapagliflozin treatment group showed a statistically significant decrease in HbA1c compared to placebo at 24 weeks (Table 5, p<0.0001).
Table 5. Outcomes at Week 24 (LOCFa) in a placebo-controlled study comparing the add-on of dapagliflozin in patients with inadequate glycemic control with sitagliptin (alone or in combination with metformin) - see leaflet -
When dapagliflozin 10mg was administered in combination with sitagliptin, fasting blood sugar levels were statistically significantly reduced compared to placebo.
postprandial blood sugar
When 10 mg of dapagliflozin was added to sitagliptin, a decrease in 2-hour postprandial blood sugar levels was observed at 24 weeks and was maintained until 48 weeks.
4) Toxicity test information
(1) Dapagliflozin
① Carcinogenicity: Dapagliflozin did not induce tumors in mice or rats at any of the doses evaluated in the 2-year carcinogenicity study. The oral doses in mice were 5, 15, and 40 mg/kg/day for males and 2, 10, and 20 mg/kg/day for females, and the oral doses in rats were 0.5, 2, and 10 mg/kg/day for both sexes. The highest dose evaluated in mice corresponded to an AUC exposure multiple of approximately 72 (males) and 105 (female) the human AUC at the maximum recommended human dose (MRHD) of 10 mg per day. The AUC exposure in rats was approximately 131 times (males) and 186 times (females) the human AUC at MRHD.
② Mutagenicity: Dapagliflozin was negative in the Ames mutagenicity test and positive in the in vitro chromosomal abnormality test, but this was true when the concentration was over 100 mg/mL under S9 activity conditions. In particular, dapagliflozin was negative for chromosomal abnormalities in in vivo conditions in micronucleus or DNA repair tests conducted on rats at an exposure equivalent to more than 2,100 times the human exposure in MRHD. These studies support that dapagliflozin does not present a genotoxic risk to humans, given the absence of neoplastic findings in rat and mouse carcinogenicity studies.
③ Reproductive dysfunction: In tests on fertility and early embryo development in rats, 15, 75, or 300/210 mg/kg/day of dapagliflozin was administered to males (300 mg/kg/day dose was reduced to 210 mg/kg/day after 4 days), and 3, 15, or 75 mg/kg/day doses were administered to females. Dapagliflozin did not affect mating, fertility, or early embryonic development in males or females at any dose administered (fold exposure ≤1708 and 998 times the MRHD in males and females). However, at 300/210 mg/kg/day, seminal vesicle and epididymal weight decreased, sperm motility and sperm count decreased, and the number of morphologically abnormal sperm was low.
④ Teratogenicity: Direct administration to young rats during the weaning period and indirect exposure to the drug during the second half of pregnancy and lactation (the period corresponding to the second and third trimesters of pregnancy in relation to human kidney development) are associated with an increase in the severity and incidence of renal pelvis dilatation and tubular dilatation in offspring. In a toxicity test in young animals, when dapagliflozin was administered to young rats on the 21st day of life at doses of 1, 15, or 75 mg/kg/day for up to 90 days, renal pelvis dilatation and tubule dilatation were reported at all doses; Exposure to offspring at the lowest dose was more than 15 times the MRHD. These observations were associated with a dose-related increase in kidney mass and macroscopic renal hypertrophy at all doses. The renal pelvis and tubular dilatation observed in young animals were not completely reversed during a recovery period of approximately 1 month.
⑤ Early developmental disorders: In a separate study on prenatal and postnatal development, maternal rats were administered drugs (1, 15, or 75 mg/kg/day) from the 6th day of pregnancy to the 21st day after birth, and the offspring were exposed indirectly through uterus and breastfeeding. (A separate study was conducted to evaluate the effects of dapagliflozin on milk and offspring.) Increased severity or incidence of renal pelvic dilatation was again observed in adult offspring of dams receiving the dose, albeit only at a dose of 75 mg/kg/day (corresponding to dam and foal dapagliflozin exposures of 1415 and 137 times [human levels in MRHD], respectively). Additional developmental toxicity was limited to dose-related reductions in pup body weight, which were observed at doses above 15 mg/kg/day (pup exposure greater than 29 times [human levels in MRHD]). Maternal toxicity was evident only at 75 mg/kg/day and was limited to a transient decrease in body weight and food consumption at the beginning of administration. The NOAEL for developmental toxicity, 1 mg/kg/day, is approximately 19 times the [human level in MRHD] and corresponds to maternal systemic exposure.
In additional embryo-fetal development studies in rats and rabbits, dapagliflozin was administered at intervals corresponding to key periods of organogenesis in each species. No maternal or developmental toxicity was observed in rabbits at any dose administered (20, 60, or 180 mg/kg/day); 180mg/kg/day corresponds to a systemic exposure of approximately 1191 times the MRHD. In rats, dapagliflozin was not embryonic lethal or teratogenic up to a dose of 75 mg/kg/day (approximately 1441 times the MRHD). Maternal and developmental toxicity was associated at a dose of 150 mg/kg/day (approximately 2344 times [human level in MRHD]). Maternal toxicity includes mortality, abnormal clinical signs, and reduction in body weight and food consumption. Developmental toxicities include embryo-fetal mortality, increased fetal malformations and skeletal dysmorphic events, and reduced fetal weight. The malformations are macrovascular malformation, costal and central spinal fusion, and sternum and central sternal duplication. The variation was mainly reduced ossification.
⑥ Animal toxicology: Most effects observed in major repeated-dose toxicity tests on rats and dogs were judged to be accompanied by pharmacologically mediated increases in urinary glucose, and included weight loss and/or decreased body weight gain rate, increased feed consumption, and increased urine volume due to osmotic diuretics. Dapagliflozin was well tolerated when administered orally to rats at a dose of 25 mg/kg/day (more than 346 times the human exposure at MRHD) for up to 6 months and to dogs at a dose of 120 mg/kg/day (more than 3200 times the human exposure at MRHD) for up to 12 months. In addition, as a result of a single-dose test of dapagliflozin, in both rat and dog toxicity tests, dapagliflozin 3-O-glucuronide metabolites were formed at an exposure level (AUC) equivalent to or higher than the expected human dapagliflozin 3-O-glucuronide exposure after administration of dapagliflozin in MRHD. The most notable nonclinical toxicological findings in rats, increased cancellous bone and tissue mineralization (related to increased serum calcium), were observed only at high exposure multiples (>2100-fold based on human exposure at MRHD). Despite reaching an exposure multiple of more than 3200 times the human exposure at MRHD, there were no dose limitations or target organ toxicities in the 12-month dog study.
(2) Sitagliptin
① Carcinogenicity, mutagenicity, fertility: A carcinogenicity test was conducted on male and female rats at doses of 50, 150, and 500 mg/kg/day of sitagliptin for 2 years. The incidence of combined liver adenoma/carcinoma increased in both sexes, and in females, the incidence of liver cancer increased at 500 mg/kg. This dose is almost 60 times the maximum recommended human dose (MRHD) of 100 mg/day based on AUC comparison. Liver tumors were not observed at 150 mg/kg, which is nearly 20 times the maximum recommended human dose.
A carcinogenicity test was conducted on male and female mice at doses of 50, 125, 250, and 500 mg/kg/day of sitagliptin for 2 years. At 500 mg/kg, which is almost 70 times the maximum recommended human dose, there was no increase in tumor occurrence in any organ. Sitagliptin was not shown to be mutagenic or cause chromosomal abnormalities in a series of genotoxicity studies, such as reverse mutation (Ames) test using bacteria, in vitro chromosomal aberration test and in vitro cytogenetic analysis using CHO cells, in vitro alkaline elution assay in rat liver cells, and in vivo micronucleus test using mouse hematopoietic cells.
In a rat fertility test, doses of 125, 250, and 1000 mg/kg were administered to males for 4 weeks before mating, at the time of mating, and until the end of mating (about 8 weeks in total), and to females, it was orally administered from 2 weeks before mating until the 7th day of pregnancy. No fertility abnormalities were observed at 125 mg/kg (about 12 times the maximum recommended human dose). At high doses (25 and 100 times the maximum recommended human dose), a dose-independent increase in resorption was observed in females.
② Reproductive toxicity: In reproductive toxicity tests conducted in rats and rabbits, there was no damage to fertility or fetuses when sitagliptin was administered at a dose of 125 mg/kg (corresponding to 12 times the maximum recommended human dose). However, there are no controlled test results for pregnant women, and the results of reproductive toxicity tests in animals do not always predict reactions in humans, so use in pregnant women is not recommended.
When sitagliptin was administered to pregnant female rats and rabbits on days 6 to 20 of pregnancy (organ formation period), there were no teratogenic effects when administered at doses up to 250 mg/kg in rats and up to 125 mg/kg in rabbits, or approximately 30 or 20 times the maximum recommended human dose of 100 mg/day based on AUC comparison. When administered orally in rats at a dose of 1000 mg/kg/day (corresponding to approximately 100 times the exposure of 100 mg/day, the maximum recommended dose in humans), the incidence of rib hypoplasia in offspring increased with higher doses.
Body weight decreased in both male and female rat pups that were orally administered at a dose of 1000 mg/kg/day from the 6th day of pregnancy to the 21st day of lactation. No abnormalities in function or behavior were observed.
About 45% of sitagliptin passed through the placenta at 2 hours and 80% at 24 hours after administration to pregnant rats. In rabbits, the rate was approximately 66% at 2 hours and 30% at 24 hours after administration.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
28 tablets/box ((7 tablets/PTP)X4)
7. Period of use
24 months from date of manufacture
- Active ingredients:
Dapagliflozin Bis L-Proline (in-house specification) ----- 15.63mg (10mg as dapagliflozin)
Sitagliptin phosphate monohydrate (USP) ----- 128.48mg (100mg as sitagliptin)
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: Anhydrous calcium hydrogen phosphate, microcrystalline cellulose, magnesium stearate, Opadry white (03B28796), low-substituted hydroxypropyl cellulose, carnauba lead, colloidal silicon oxide, croscarmellose sodium, hydroxypropyl cellulose, D-mannitol
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve glycemic control in patients with type 2 diabetes who are suitable for combined administration of sitagliptin and dapagliflozin.
3. Dosage and dosage
This drug can be administered 1 tablet once a day, regardless of meal, to patients taking 100 mg of sitagliptin and 10 mg of dapagliflozin. Tablets should be swallowed whole.
special group
Patients with renal impairment
The effectiveness and safety of this drug depend on renal function, and it is recommended to periodically evaluate renal function before and after administration of this drug.
- If the estimated glomerular filtration rate (eGFR) is more than 45mL/min/1.73m2, dose adjustment is not necessary.
- Do not administer this drug if the estimated glomerular filtration rate (eGFR) is less than 45mL/min/1.73m2.
Hepatic impairment patients
No dose adjustment is necessary for patients with mild or moderate hepatic impairment. The use of this drug is not recommended for patients with severe hepatic impairment.
4. Precautions for use
1. Warning
1) Sitagliptin
(1) Hypersensitivity reaction
Severe hypersensitivity reactions have been reported in patients receiving post-marketing sitagliptin, including anaphylaxis, angioedema, and exfoliative skin disorders, including Stevens-Johnson syndrome. Because they are voluntarily reported from an unspecified population, it is generally not possible to reliably estimate their incidence or establish a causal relationship with drug exposure. The onset of this reaction occurred within the first 3 months of drug treatment and has also been reported after the first dose. If hypersensitivity reaction is suspected, discontinue this drug, evaluate other potential reasons for the occurrence, and implement other diabetes treatment (see 2. Do not administer to the following patients and 4. Adverse reactions, 2) Sitagliptin, (2) Post-marketing adverse reactions).
(2) Pancreatitis
Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis, has been reported in patients treated with sitagliptin (see section 4. Adverse reactions, 2) Sitagliptin). After starting treatment with this drug, carefully observe whether symptoms of pancreatitis appear. If pancreatitis is suspected, administration of this drug and other suspected drugs should be discontinued.
2. Do not administer to the following patients
1) Patients with a history of hypersensitivity to the main ingredients or excipients of this drug (including anaphylaxis or angioedema (see 1. Warning section))
2) Patients with type 1 diabetes or diabetic ketoacidosis
3) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
4) Patients on dialysis
3. Administer with caution to the following patients:
1) Dapagliflozin
(1) Administration in patients with decreased body fluid volume and renal dysfunction
Dapagliflozin may cause a decrease in intravascular blood volume, which may manifest as symptomatic hypotension or sudden and temporary changes in creatinine. In foreign post-marketing surveillance, acute kidney injury was reported in patients receiving SGLT-2 inhibitors, including dapagliflozin, and some required hospitalization and dialysis. The risk of hypovolemia or hypotension may increase in patients with renal dysfunction (eGFR less than 60mL/min/1.73m2), the elderly, and those using loop diuretics. For patients with these characteristics, it is necessary to evaluate body fluid status and renal function before starting dapagliflozin administration, and after starting administration, monitor symptoms and signs of hypotension and renal function.
The glucose-lowering efficacy of dapagliflozin depends on renal function. Efficacy is reduced in patients with moderate renal impairment, and dapagliflozin is not recommended solely for glycemic control in patients with type 2 diabetes and an eGFR below 45 mL/min/1.73 m². Among patients with moderate renal impairment, elevated creatinine, phosphorus and parathyroid hormone (PTH) levels and hypotension were reported more frequently with dapagliflozin than with placebo.
2) Sitagliptin
(1) Patients with renal impairment: Sitagliptin is excreted through the kidneys. To achieve blood levels similar to those in patients with normal renal function, lower doses are recommended in patients with a glomerular filtration rate [eGFR] <45 mL/min/1.73 m2 and in patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis.
4. Adverse reactions
1) Dapagliflozin
(1) Summary of safety profile
In clinical studies of patients with type 2 diabetes, more than 15,000 patients received dapagliflozin.
Safety and tolerability were assessed through a predefined pooled analysis of 13 short-term (up to 24 weeks) placebo-controlled trials involving 2,360 patients administered 10 mg of dapagliflozin and 2,295 patients administered placebo.
In the clinical trial to evaluate the cardiovascular effects of dapagliflozin in patients with type 2 diabetes (DECLARE), 8,574 people were administered dapagliflozin 10 mg and 8,569 people were administered placebo, and the median exposure period was 48 months. There were a total of 30,623 patient-years of dapagliflozin exposure.
The most commonly reported adverse reactions throughout clinical studies were genital infections.
(2) List of adverse reactions
The following adverse reactions were observed in placebo-controlled clinical trials. There were no dose-related adverse reactions. The adverse reactions listed below are classified according to frequency and organ system (SOC). Frequency of presentation was defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), and unknown (cannot be assessed from available data).
Table 1 Adverse events in placebo-controlled trials? See documentation -
(3) Description of specific adverse reactions
① Vulvovaginitis, balanitis and related genital infections
Pooled safety data from 13 clinical trials showed that vulvovaginitis, balanitis, and related genital infections were reported in 5.5% and 0.6% of subjects receiving dapagliflozin 10 mg and placebo, respectively. Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women (8.4% and 1.2% in the dapagliflozin and placebo groups, respectively), and subjects with a prior medical history were more likely to have recurrent infections.
In the DECLARE clinical trial, the number of serious adverse events of genital infection was very small and evenly distributed (2 patients each in the dapagliflozin and placebo groups).
In the DAPA-HF clinical trial, no serious adverse events of genital infection were reported in the dapagliflozin group and one case was reported in the placebo group. There were 7 patients (0.3%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection.
In the DAPA-CKD clinical trial, serious adverse events of genital infection were reported in 3 cases (0.1%) in the dapagliflozin group and none in the placebo group. There were 3 patients (0.1%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection. In patients without diabetes, no serious adverse events of genital infection or adverse events leading to discontinuation of treatment were reported.
② Low blood sugar
The frequency of hypoglycemia in clinical trials in patients with diabetes depended on the type of baseline therapy used in each trial.
In additional combination studies of dapagliflozin administered alone, metformin, or sitagliptin (metformin alone or in combination), the frequency of mild hypoglycemic episodes was similar (<5%) between treatment groups, including placebo, up to 102 weeks of treatment. In a comprehensive analysis of safety information from 1,169 patients evaluated for dapagliflozin and saxagliptin combination therapy, the overall incidence of hypoglycemia was low at 24 weeks (≤1.8% in all groups).
In all trials, major hypoglycemic events were uncommon and equivalent between dapagliflozin and placebo groups. The incidence of hypoglycemia was higher in studies with the addition of sulfonylurea and in studies with the addition of insulin.
In the glimepiride add-on study, mild hypoglycemic episodes were reported more frequently at weeks 24 and 48 in those receiving dapagliflozin 10 mg and glimepiride (6.0% and 7.9%, respectively) compared to those receiving placebo and glimepiride (2.1% and 2.1%, respectively).
In the insulin add-on combination study, major hypoglycemic episodes were reported in 0.5% and 1.0% of patients receiving dapagliflozin 10 mg in combination with insulin at weeks 24 and 104, respectively, and in patients receiving placebo in combination with insulin, major hypoglycemic episodes were reported in 0.5% of cases at weeks 24 and 104. Mild hypoglycemic episodes were reported in 40.3% and 53.1% of patients receiving dapagliflozin 10 mg in combination with insulin at weeks 24 and 104, respectively, and in 34.0% and 41.6% of patients receiving placebo in combination with insulin.
In an add-on therapy trial of metformin and sulfonylureas, no major episodes of hypoglycemia were reported by week 24. Mild hypoglycemic episodes were reported in 12.8% of subjects receiving dapagliflozin 10 mg plus metformin and sulfonylurea and 3.7% of subjects receiving placebo plus metformin and sulfonylurea.
The DECLARE trial showed that dapagliflozin therapy compared with placebo did not increase the risk of major hypoglycemic events. Major hypoglycemic events were reported in 58 patients (0.7%) in the dapagliflozin group and 83 patients (1.0%) in the placebo group.
In the DAPA-HF clinical trial, major hypoglycemic events were reported in 4 patients (0.2%) each in the dapagliflozin and placebo groups, and occurred only in patients with type 2 diabetes.
In the DAPA-CKD clinical trial, major hypoglycemic events were reported in 14 patients (0.7%) in the dapagliflozin group and 28 patients (1.3%) in the placebo group, and were observed only in patients with type 2 diabetes.
③ Reduction in body fluid volume
According to pooled safety data from 13 clinical trials, drug reactions suggestive of volume loss (including dehydration, hypovolemia, or hypotension) were reported in 1.1% and 0.7% of subjects receiving dapagliflozin 10 mg and placebo, respectively; Serious reactions, occurring in less than 0.2% of subjects, were evenly distributed between the dapagliflozin 10 mg and placebo groups.
In the DECLARE clinical trial, the number of patients who developed adverse events suggesting a decrease in body fluid volume was evenly distributed among treatment groups: 213 (2.5%) in the dapagliflozin group and 207 (2.4%) in the placebo group. Serious adverse events were reported in 81 patients (0.9%) in the dapagliflozin group and 70 patients (0.8%) in the placebo group. Adverse events were generally evenly distributed between treatment groups across subgroups, including age, use of diuretics, blood pressure, and use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In the patient population with a baseline estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m2, 19 serious adverse events suggesting volume loss were reported in the dapagliflozin group and 13 cases in the placebo group.
In the DAPA-HF clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 170 (7.2%) in the dapagliflozin group and 153 (6.5%) in the placebo group. The number of patients with serious adverse events suggesting volume loss was lower in the dapagliflozin group (23 [1.0%]) than in the placebo group (38 [1.6%]). Similar results were observed across subgroups including age, presence of diabetes at baseline, baseline eGFR, and systolic blood pressure.
In the DAPA-CKD clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 120 (5.6%) in the dapagliflozin group and 84 (3.9%) in the placebo group. The number of patients with serious adverse events suggesting a decrease in body fluid volume was 16 (0.7%) in the dapagliflozin group and 15 (0.7%) in the placebo group.
④ Diabetic ketoacidosis
In the DECLARE clinical trial (median dapagliflozin exposure period of 48 months), 27 cases of diabetic ketoacidosis were reported in the patient group administered dapagliflozin 10 mg and 12 cases in the placebo group. Occurrence points were evenly distributed throughout the study period. Of the 27 patients who developed diabetic ketoacidosis in the dapagliflozin group, 22 were taking insulin at the time the case occurred. Factors causing diabetic ketoacidosis appeared as expected in the type 2 diabetes patient population (see ‘4. General precautions, 3) Ketoacidosis’).
In the DAPA-HF clinical trial, diabetic ketoacidosis cases were reported in 3 patients with type 2 diabetes in the dapagliflozin group and no cases in the placebo group.
In the DAPA-CKD clinical trial, no cases of diabetic ketoacidosis were reported in the dapagliflozin group and two cases of type 2 diabetes were reported in the placebo group.
⑤ Urinary tract infection
Pooled safety data from 13 clinical trials showed that urinary tract infections were reported more frequently in the dapagliflozin 10 mg group compared to the placebo group (4.7% vs 3.5%, respectively). Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women, and subjects with a previous medical history were more likely to develop recurrent infections.
In the DECLARE clinical trial, 79 cases (0.9%) of serious adverse events of urinary tract infection were reported in the dapagliflozin 10 mg treatment group, which was less frequent than the 109 cases (1.3%) in the placebo group.
In the DAPA-HF clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was small, with no significant difference between the two groups: 14 patients (0.6%) in the dapagliflozin group and 17 patients (0.7%) in the placebo group. There were 5 patients (0.2%) in each of the dapagliflozin and placebo groups who discontinued treatment due to adverse events of urinary tract infection.
In the DAPA-CKD clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was 29 (1.3%) in the dapagliflozin group and 18 (0.8%) in the placebo group. There were 8 patients (0.4%) in the dapagliflozin group and 3 (0.1%) in the placebo group who discontinued treatment due to adverse events of urinary tract infection.
⑥ Increased creatinine
Adverse reactions associated with increased creatinine were classified as decreased renal creatinine clearance, renal impairment, increased blood creatinine, and decreased glomerular filtration rate. According to pooled safety data from 13 clinical trials, these adverse reactions were reported in 3.2% and 1.8% of subjects receiving dapagliflozin 10 mg and placebo, respectively. In normal subjects or patients with mild renal failure (eGFR 60 mL/min/1.73 m2 or higher), these adverse reactions were reported in 1.3% and 0.8% of patients receiving dapagliflozin 10 mg and placebo, respectively. These adverse reactions were reported more frequently in patients with an eGFR greater than 30 mL/min/1.73 m2 but less than 60 mL/min/1.73 m2 (18.5% and 9.3% for dapagliflozin 10 mg and placebo, respectively).
In the subsequent evaluation of patients with kidney-related adverse events, changes in serum creatinine of ≤ 0.5 mg/dL from baseline were observed in most patients. Increased creatinine usually occurs transiently during treatment or resolves after treatment is discontinued.
In the DECLARE clinical trial, which included elderly patients and patients with renal impairment (eGFR less than 60 mL/min/1.73m2), eGFR decreased over time in both the dapagliflozin group and the placebo group. After 1 year, the average eGFR was slightly lower in the dapagliflozin group, and after 4 years, the average eGFR in the dapagliflozin group was slightly higher than the placebo group.
In the DAPA-HF clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial decrease in mean eGFR was -4.3 mL/min/1.73 m2 in the dapagliflozin group and -1.1 mL/min/1.73 m2 in the placebo group. At 20 months, the change from baseline in eGFR was similar between treatment groups (dapagliflozin group -5.3 mL/min/1.73 m2, placebo group -4.5 mL/min/1.73 m2).
In the DAPA-CKD clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial (day 14) decrease in average eGFR was -4.0 mL/min/1.73 m2 in the dapagliflozin group and -0.8 mL/min/1.73 m2 in the placebo group. The change from baseline in eGFR at 28 months was -7.4 mL/min/1.73 m2 in the dapagliflozin group and -8.6 mL/min/1.73 m2 in the placebo group.
⑦ Perineal gangrene (Fournier’s gangrene)
During post-marketing surveillance, cases of Fournier's gangrene have been reported in patients receiving SGLT2 inhibitors, including dapagliflozin (see 4. General precautions, 12) Perineal gangrene (Fournier's gangrene).
In the DECLARE clinical trial involving 17,160 patients with type 2 diabetes and a median exposure period of 48 months, a total of 6 cases of Fournier's gangrene were reported, including 1 case in the dapagliflozin group and 5 cases in the placebo group.
(4) Post-marketing surveillance
The following are additional adverse drug reactions confirmed after the marketing of dapagliflozin. This adverse drug reaction was reported voluntarily from an uncharacteristic large population, so it is not possible to reliably predict its incidence.
- Ketoacidosis (including diabetic ketoacidosis)
- Urosepsis and pyelonephritis
- Acute kidney injury and renal dysfunction
- Rash: Rash includes the following representative terms in order of frequency in clinical studies: rash, generalized rash, pruritic rash, macular rash, maculopapular rash, pustular rash, bullous rash, and erythematous rash. In active-controlled and placebo-controlled clinical studies (5,936 people in the dapagliflozin group, 3,403 people in all control groups), the frequency of rash was similar in the dapagliflozin group (1.4%) and all control groups (1.4%) and was ‘common.’
(5) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,027 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 26.59% (805/3,027 people, total 1,122 cases) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence. - Refer to manual -
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence. - Refer to manual -
2) Sitagliptin
(1) Clinical trials
① Because clinical trials are conducted under wide and diverse conditions, the incidence of adverse reactions observed in clinical trials cannot be directly compared to the rates in clinical trials of other drugs, and cannot reflect the rates observed under actual use environments.
In clinical trials of sitagliptin, when sitagliptin was administered as monotherapy or combination therapy (metformin or pioglitazone or rosiglitazone and metformin), the incidence of adverse reactions and hypoglycemia was generally similar to that reported for placebo. Cases where treatment was discontinued due to adverse reactions were similar to those in the placebo group.
During glimepiride or glimepiride and metformin combination therapy, the frequency of adverse reactions in the sitagliptin group was higher than the placebo group (Table 4). This is partly due to the high incidence of hypoglycemia in the sitagliptin administration group. Discontinuation of treatment due to adverse reactions was similar to that in the placebo group.
Two placebo-controlled monotherapy studies conducted for 18 and 24 weeks included groups receiving sitagliptin 100 mg and 200 mg daily and placebo. Five additional placebo-controlled combination therapy studies administered 100 mg of sitagliptin or placebo daily in combination with stable doses of metformin, pioglitazone, rosiglitazone, and metformin, glimepiride (±metformin), or insulin (±metformin), respectively.
In these clinical trials, except for hypoglycemia and regardless of causality assessment, adverse reactions reported at a frequency of 5% or more among patients taking sitagliptin 100 mg daily for 18 weeks and more frequently than placebo are listed in Table 2. The frequency of occurrence of hypoglycemia is shown in Table 4.
Table 2. Placebo-controlled clinical trials with sitagliptin monotherapy or combination therapy (pioglitazone, or rosiglitazone and metformin, or glimepiride (±metformin)): Adverse reactions excluding hypoglycemia, which were reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment - see description -
In patients who received sitagliptin and metformin in combination for 24 weeks, there were no adverse reactions reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment.
In patients who received sitagliptin in combination with a stable dose of insulin (±metformin) for 24 weeks, there were no adverse reactions except hypoglycemia, which was reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment (see Table 4 for hypoglycemia). In patients receiving additional sitagliptin during another 24-week insulin intensification period (±metformin), the adverse reaction reported at a frequency greater than 5% and more frequently than placebo, regardless of causality assessment, was diarrhea (5.2% for this drug; 3.3% for placebo).
In patients who received sitagliptin in combination with rosiglitazone and metformin for 54 weeks, adverse reactions reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment, were: upper respiratory tract infection (sitagliptin 15.5%, placebo 6.2%), nasopharyngitis (11.0%, 9.3%), peripheral edema (8.3%, 5.2%), and Headache (5.5%, 4.1%).
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the occurrence of specific gastrointestinal adverse reactions in patients treated with sitagliptin was as follows: abdominal pain (sitagliptin 100 mg 2.3%, placebo 2.1%), nausea (sitagliptin 100 mg 1.4%, placebo 0.6%), Diarrhea (sitagliptin 100mg 3.0%, placebo 2.3%)
In a placebo-controlled factorial design clinical trial conducted for 24 weeks, adverse reactions reported at a frequency of 5% or more or more frequently than placebo, regardless of causality assessment, upon initial co-administration of sitagliptin and metformin are shown in Table 3.
Table 3. Initial combination therapy of sitagliptin and metformin: Adverse reactions reported at a frequency of more than 5% and more frequently than sitagliptin alone, metformin alone, and placebo, regardless of causality assessment? See documentation -
No clinically significant changes in vital signs or ECG (including QTc interval) were observed with sitagliptin administration.
② Pancreatitis
When the results of 19 double-blind clinical trials of 10,246 patients randomly assigned to sitagliptin 100 mg/day (N=5429) or the corresponding control group (active comparator or placebo) (N=4817) were pooled and analyzed, the incidence of acute pancreatitis in each group was 0.1 per 100 patient-years (in the sitagliptin group) reported in 4 patients out of 4708 patient-years and in the control group in 4 patients out of 3942 patient-years). In the TECOS cardiovascular safety trial, the incidence of acute pancreatitis was reported to be 0.11 (23/7,332, 25 cases) per 100 patient-years in the sitagliptin group and 0.06 (12/7,339, 17 cases) per 100 patient-years in the placebo group. (See 1. Warning, 1) Sitagliptin, (2) Pancreatitis section, and TECOS Cardiovascular Safety Clinical Trial section)
③ TECOS cardiovascular safety clinical trial (TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin)
The intent-to-treat (ITT) group of the cardiovascular safety clinical trial of sitagliptin included 7,332 patients who received sitagliptin 100 mg daily (or 50 mg daily if eGFR≥30 and <50 mL/min/1.73 m2 at baseline) and 7,339 patients who received placebo. In this trial, sitagliptin or placebo was administered in addition to usual treatment in each country related to HbA1c and cardiovascular (CV) risk factors. Sitagliptin administration did not increase the risk of hospitalization due to major cardiovascular disease or heart failure. The reported incidence of serious adverse reactions was similar at 12.7% in the sitagliptin group and 12.4% in the placebo group.
Severe hypoglycemia was reported in 2.2% of the sitagliptin group (160 patients; 0.78 per 100 patient-years) and 1.9% of the placebo group (143 patients; 0.70 per 100 patient-years). Among patients receiving insulin and/or a sulfonylurea, the incidence was 2.7% with sitagliptin (138/5,021 patients) and 2.5% with placebo (125/4,931 patients). Among patients not receiving insulin or a sulfonylurea, the incidence was 1.0% with sitagliptin (22/2,311 patients) and 0.7% with placebo (18/2,408 patients). Confirmed acute pancreatitis occurred in 0.3% of the sitagliptin group and 0.2% of the placebo group.
④ Low blood sugar
In all studies (9), hypoglycemic adverse events were based on reports of symptomatic hypoglycemia. Although blood sugar measurement was not necessarily required, most reports of hypoglycemia (74%) were below 70 mg/dL when measured. When sitagliptin was administered in combination with a sulfonylurea or insulin, the proportion of patients with one or more hypoglycemic adverse events was higher than in the placebo group (see Table 4).
Table 4. Placebo-controlled trials of sitagliptin in combination with glimepiride (±metformin) or insulin (±metformin): Incidence of reported hypoglycemia, regardless of causality assessment? See documentation -
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the incidence of hypoglycemia as an adverse reaction in patients administered sitagliptin 100 mg was similar to that of placebo (1.2% for sitagliptin 100 mg, 0.9% for placebo).
In a clinical trial of the combination therapy of sitagliptin, rosiglitazone, and metformin, the incidence of hypoglycemia up to 18 weeks was 2.2% in the sitagliptin group and 0.0% in the placebo group. The incidence up to 54 weeks was 3.9% and 1.0%, respectively.
In a placebo-controlled factorial trial conducted for 24 weeks, the incidence of hypoglycemia during initial co-administration of sitagliptin and metformin was 0.6% in the placebo group, 0.6% in the sitagliptin-only group, 0.8% in the metformin-only group, and 1.6% in the sitagliptin-metformin combination group.
⑤ Laboratory tests
The incidence of laboratory adverse reactions in the group administered 100 mg of sitagliptin was 8.2%, and in the group administered placebo it was 9.8%. In clinical trials, a slight increase in white blood cell count due to an increase in neutrophils (about 200 cells/μL difference compared to placebo administration; average baseline value of about 6600 cells/μL) was observed. This difference has been shown in many, but not all, studies, and changes in laboratory values are not believed to be clinically relevant.
In a 12-week study, 91 patients with chronic renal impairment and 37 patients with moderate renal impairment were randomly assigned to sitagliptin 50 mg, and 14 patients with the same degree of renal impairment were randomized to placebo. The mean (standard error) increase in serum creatinine was 0.12 mg/dL (0.04) in the sitagliptin group and 0.07 mg/dL (0.07) in the placebo group. The clinical significance of increased serum creatinine compared to placebo is unknown.
⑥ Domestic clinical trial results
The safety and efficacy of sitagliptin were evaluated in a bridging clinical trial conducted in 530 Asians in a multinational, double-blind, randomized, placebo-controlled, parallel group study, of which 95 were Korean. The safety profile of sitagliptin in Koreans was overall similar to that of placebo and did not show significant differences from the results reported in previous clinical trials.
(2) Post-marketing adverse reactions
The following are additional adverse reactions confirmed after the marketing of sitagliptin. Because these adverse reactions are voluntarily reported from an unspecified population, it is generally not possible to reliably predict their frequency or establish a causal relationship with drug exposure. Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, cutaneous angiitis and exfoliative skin diseases including Stevens-Johnson syndrome (see section 1. Warnings), elevated liver enzymes; Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis (see 1. Warning, 1) Sitagliptin, (2) Pancreatitis); Deterioration of renal function, including acute renal failure (sometimes requiring dialysis); upper respiratory tract infection; nasopharyngitis; constipation; puke; headache; Severe and disabling arthralgia (see sections 5. General precautions, 2) Sitagliptin, (2) Severe and disabling arthralgia); Bullous pemphigoid (see section 5. General precautions, 2) Sitagliptin, (3) Bullous pemphigoid); myalgia; Pain in limbs; back pain; interstitial lung disease; pruritus; It is thrombocytopenia. During post-marketing use, rhabdomyolysis was reported when taken with statin drugs. (Domestic clue information analysis and evaluation results)
(3) Domestic post-marketing survey results
① As a result of a use result survey conducted on 3,453 people over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 4.87% (168/3,453 people) [232 cases] regardless of causal relationship, and among these, the incidence of adverse drug reactions for which a causal relationship with sitagliptin could not be ruled out was 1.56% (54/3,453 people). [64 cases] ‘hypoglycemia’ at 0.26% (9 people/3,453 people) [9 cases], ‘indigestion’ and ‘dizziness’ at 0.12% each (4/3,453 people) [4 cases], ‘increased ALT’, ‘AST increase’, ‘diarrhea’, ‘nausea’, and ‘headache’ at 0.09% each (3/3,453 people) [3 cases], etc. It has been reported.
Serious adverse events were 0.12% (4/3,453 people) [5 cases] regardless of causal relationship, with ‘pneumonia’, ‘diabetic complications’, ‘metabolic acidosis’, ‘fall’, and ‘cardiac arrest’ occurring at 0.03% (1/3,453 people) [1 case] each. Among these, the serious adverse drug reaction was ‘diabetic complications’ at 0.03%. (1/3,453 people)[1 case] reported.
Unexpected adverse events were reported at 3.04% (105/3,453 people) [137 cases] regardless of causal relationship, ‘indigestion’ at 0.32% (11/3,453 people) [12 cases], ‘dizziness’ at 0.23% (8/3,453 people) [8 cases], ‘increased blood triglyceride’, and ‘gastritis’. 0.17% (6/3,453 people) [6 cases] were reported, and among these, unexpected adverse drug reactions for which a causal relationship with sitagliptin cannot be ruled out were 0.93% (32/3,453 people) [35 cases], ‘indigestion’ and ‘dizziness’ at 0.12% (4/3,453 people) [4 cases] respectively, ‘increased blood triglycerides’, ‘Increased low-density lipoprotein’ and ‘hyperglycemia’ were reported in the order of 0.06% (2/3,453 people) [2 cases] each.
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for sitagliptin with the adverse event reporting data reported for all domestically approved drugs at the end of re-examination, the following are newly identified adverse events that were statistically significantly more reported for sitagliptin than those reported for all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
· Gastrointestinal disorders: indigestion, gastritis
· Metabolic and nutritional diseases: weight loss
· Common cardiovascular diseases: high blood pressure
· Metabolic and nutritional diseases: hypernatremia
· Mental illness: erectile dysfunction
5. General precautions
1) Dapagliflozin
(1) Use for patients with hepatic impairment
Clinical trial experience in patients with hepatic impairment is limited. Dapagliflozin exposure is increased in patients with severe hepatic impairment.
(2) Use in patients at risk of volume loss and/or hypotension
Due to the mechanism of action of dapagliflozin, an increase in urination leading to a slight decrease in blood pressure was observed in clinical studies. This may be more noticeable in patients with very high blood sugar levels.
Caution should be exercised in patients who may be at risk for drug-induced reductions in blood pressure, such as patients receiving antihypertensive treatment and a history of hypotension or elderly patients.
If there are comorbidities that may cause volume loss (e.g., gastrointestinal disease), close monitoring of fluid volume status (e.g., physical examination, blood pressure measurement, and laboratory tests including hematocrit and electrolyte testing) is recommended. For patients exhibiting volume loss, temporary discontinuation of dapagliflozin is recommended until volume loss is restored.
(3) Ketoacidosis
Reports of serious, life-threatening ketoacidosis requiring prompt hospitalization have been identified in patients with type 1 and type 2 diabetes treated with SGLT2 inhibitors, including dapagliflozin. Fatal cases of ketoacidosis have been reported in patients treated with dapagliflozin.
Dapagliflozin-associated ketoacidosis may occur even when blood glucose is below 250 mg/dL. Patients treated with dapagliflozin who show signs and symptoms consistent with severe metabolic acidosis should therefore be evaluated for ketoacidosis regardless of their blood glucose level. If ketoacidosis is suspected, discontinue dapagliflozin, assess the patient’s condition and initiate treatment promptly.
Treatment of ketoacidosis may require insulin, fluid, and carbohydrate replacement.
In many post-marketing reports, particularly in patients with type 1 diabetes, the presence or absence of ketoacidosis was not immediately identified and the introduction of treatment was delayed because the observed blood glucose levels were lower than those typically expected for diabetic ketoacidosis (most often less than 250 mg/dL). Diabetes and ketoacidosis may persist longer than is generally expected, and urinary glucose secretion may persist for up to 3 days after discontinuation of treatment. However, there have been post-marketing reports that diabetes and ketoacidosis persisted for more than 6 days and up to 2 weeks after discontinuation of SGLT2 inhibitor treatment.
Symptoms and signs of ketoacidosis are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, decreased appetite, abdominal pain, malaise, and difficulty breathing. Some reports have identified factors predisposing to ketoacidosis to include reduced insulin dose, acute febrile illness, restricted calorie intake due to illness or surgery, ketogenic diet, pancreatic disorders causing insulin deficiency (e.g., type 1 and 2 diabetes, pancreatitis, or history of pancreatic surgery), and alcohol abuse.
Before starting dapagliflozin treatment, factors that may predispose to ketoacidosis, including decreased insulin secretion, calorie restriction, and alcohol abuse, should be considered. Monitor patients treated with dapagliflozin for the development of ketoacidosis, and consider temporarily discontinuing dapagliflozin administration if clinical situations predisposing to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery) occur.
Inform patients about the risk of diabetic ketoacidosis, its risk factors, signs and symptoms, and the fact that it may occur even when blood glucose is below 250 mg/dL. It is recommended that patients be able to monitor blood ketones and receive education on when monitoring is needed. Patients should seek prompt treatment if ketoacidosis is suspected.
(4) Urosepsis and pyelonephritis
Serious urinary tract infections, including urosepsis and pyelonephritis, have been reported post-marketing in patients using dapagliflozin and other SGLT2 inhibitors. SGLT2 inhibitor therapy increases the risk of urinary tract infections. If necessary, evaluate the patient's signs and symptoms of urinary tract infection and promptly treat them.
(5) Reproductive infections (including fungi)
Dapagliflozin increases the risk of genital infections (including fungal). Patients with a history of genital infections (including fungal) are more likely to develop genital infections (including fungal). Observe and treat appropriately.
(6) Elderly patients
Elderly patients are more likely to have renal impairment or be taking antihypertensive drugs that can cause changes in renal function, such as angiotensin-converting enzyme inhibitors (ACE-I) and type 1 angiotensin II receptor inhibitors (ARBs). The same recommendations regarding renal function apply to elderly patients as to all patients.
Elderly patients may be at higher risk for volume loss and are more likely to be taking diuretics.
From a pharmacokinetic perspective, there are insufficient data to make conclusions regarding blood drug exposure in patients over 70 years of age.
(7) Urine laboratory evaluation
Patients receiving dapagliflozin will test positive for urinary glucose due to its mechanism of action.
(8) Use of drugs known to cause hypoglycemia
Insulin secretagogues such as insulin and sulfonylureas cause hypoglycemia. Therefore, when used in combination with dapagliflozin, the dose of insulin or insulin secretagogue may need to be reduced to reduce the risk of hypoglycemia.
(9) SGLT2 inhibitors such as dapagliflozin may theoretically worsen the condition of patients with underlying bladder diseases that may affect urinary function by increasing urine output. Therefore, caution is required when prescribing SGLT2 inhibitors such as dapagliflozin to these patients.
(10) Weight loss
In a 24-week, placebo-controlled study of dapagliflozin monotherapy in patients with inadequately controlled type 2 diabetes, the change in body weight from baseline was −3.16 kg with dapagliflozin and −2.19 kg with placebo, indicating greater weight loss with dapagliflozin.
(11) Lower extremity amputation
In long-term clinical studies of other SGLT2 inhibitors in patients with type 2 diabetes, an increase in lower extremity amputations (mainly toes) was observed. It has not been confirmed whether this case applies to the entire series. It is important to discuss routine preventive foot care with patients with diabetes.
(12) Perineal gangrene (Fournier’s gangrene)
In post-marketing surveillance of diabetic patients taking SGLT2 inhibitors, rare cases of serious, life-threatening perineal gangrene requiring prompt surgical intervention were reported [4. Adverse reactions, 1) Dapagliflozin, (3) Description of specific adverse reactions, ⑦ Perineal gangrene (Fournier gangrene). Perineal gangrene has been reported in both men and women, resulting in hospitalization, multiple surgeries, and death.
If a patient receiving dapagliflozin develops pain, soreness, erythema, or swelling around the genitals or perineum along with fever and discomfort, perineal gangrene should be checked. If perineal gangrene is suspected, broad-spectrum antibiotic treatment should be started immediately and surgical resection should be performed if necessary. Administration of dapagliflozin should be discontinued, blood sugar levels should be closely monitored, and appropriate alternative treatment should be implemented to control blood sugar.
2) Sitagliptin
(1) Co-administration with drugs known to cause hypoglycemia: As is typical for co-administration with other hypoglycemic agents, hypoglycemia was observed when sitagliptin was co-administered with insulin or sulfonylurea (see section 4. Adverse reactions, 2) Sitagliptin). To reduce the risk of sulfonylurea- or insulin-induced hypoglycemia, a dose reduction of sulfonylureas or insulin may be considered.
(2) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
(3) Bullous pemphigoid
In post-marketing surveillance in patients taking DPP-4 inhibitors, cases of bullous pemphigus requiring hospitalization have been reported. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be informed to immediately report to their doctor if blisters or sores occur while taking sitagliptin. If bullous pemphigus is suspected, sitagliptin should be discontinued and the patient should be referred to a dermatologist for diagnosis and appropriate treatment.
6. Interaction
1) Dapagliflozin
(1) Pharmacodynamic interaction
① Diuretics: Dapagliflozin may increase the diuretic effect of thiazides and loop diuretics and may increase the risk of dehydration and hypotension.
② Insulin and insulin secretion stimulants: Insulin secretion stimulants such as insulin and sulfonylurea can cause hypoglycemia. Therefore, to reduce the risk of hypoglycemia when administered in combination with dapagliflozin, the dose of insulin or insulin secretagogue may need to be reduced.
2) Pharmacokinetic interactions
① The metabolism of dapagliflozin is mainly accomplished through glucuronide conjugation mediated by UDP-glucuronidase 1A9 (UGT1A9).
② In laboratory (in-vitro) studies, dapagliflozin did not inhibit cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, or induce CYP1A2, CYP2B6, or CYP3A4. Therefore, dapagliflozin is not expected to alter the metabolic excretion of drugs metabolized by these enzymes when coadministered with these drugs.
(3) Effects of other medicines on dapagliflozin
① As a result of an interaction study conducted on healthy subjects mainly using a single-dose design, the pharmacokinetics of dapagliflozin were not changed by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
② After co-administering dapagliflozin with rifampicin (an inducer of various active transporters and drug-metabolizing enzymes), a 22% decrease in dapagliflozin systemic exposure (AUC) was observed, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended. Clinically relevant effects are not expected with other inducers (e.g., carbamazepine, phenytoin, phenobarbital).
③ After co-administering dapagliflozin with mefenamic acid (an inhibitor of UGT1A9), systemic exposure to dapagliflozin increased by 55%, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended.
(4) Effect of dapagliflozin on other medicines
Dapagliflozin may increase renal excretion of lithium and decrease blood lithium concentrations. Serum lithium concentrations should be monitored more frequently upon initiation of dapagliflozin and after dose changes. Refer the patient to the doctor who prescribed lithium to monitor serum lithium levels.
In interaction studies conducted in healthy subjects, primarily using a single-dose design, dapagliflozin had an anticoagulant effect on the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P-gp substrate), or warfarin (S-warfarin, a CYP2C9 substrate), or the anticoagulant activity of warfarin as assessed by INR. didn't change A single co-administration of dapagliflozin 20 mg and simvastatin (CYP3A4 substrate) resulted in a 19% increase in simvastatin AUC and a 31% increase in simvastatin acid AUC. Elevated simvastatin and simvastatin acid exposure are not considered clinically relevant.
(5) Other interactions
The effects of smoking, diet, herbal medicines and alcohol on the pharmacokinetics of dapagliflozin have not been studied.
(6) Pediatrics
Interaction studies were conducted only in adults.
(7) Interference with 1,5-anhydroglucitol test
The 1,5-anhydroglucitol test is not recommended as a blood sugar control monitoring test in patients taking SGLT2 inhibitors because the reliability of the measurement results is low. Different methods are used to monitor blood sugar control.
2) Sitagliptin
In drug interaction studies, sitagliptin did not have a clinically significant effect on the pharmacokinetics of the following drugs: metformin, rosiglitazone, glibenclamide, simvastatin, warfarin, and oral contraceptives. Based on this test, it is not expected to act on substrates of CYP3A4, CYP2C8, CYP2C9 and organic cation transporters.
Co-administration of metformin and sitagliptin taken twice daily in patients with type 2 diabetes does not significantly change the pharmacokinetics of sitagliptin.
Cyclosporine: When administered as a single dose in combination with 600 mg of cyclosporine, a strong p-glycoprotein inhibitor, the AUC (29%) and Cmax (68%) of sitagliptin increased, but the change in the pharmacokinetics of sitagliptin is not expected to be clinically significant. No significant interaction is expected when coadministered with cyclosporine or other p-glycoprotein inhibitors.
Digoxin: When coadministered with 100 mg of sitagliptin for 10 days, the plasma AUC (11%) and Cmax (18%) of digoxin slightly increased. Appropriate monitoring should be conducted when administering digoxin, and dose adjustment of sitagliptin and digoxin is not necessary.
7. Administration to pregnant and lactating women
1) Pregnant women
(1) Dapagliflozin: There is no data on the administration of dapagliflozin to pregnant women. Studies on rats showed toxicity to kidney development during the second and third trimesters of human pregnancy. The use of dapagliflozin in pregnant women is not recommended. Once pregnancy is confirmed, dapagliflozin administration should be discontinued.
The effects of dapagliflozin on human fertility have not been studied. In male and female rats, dapagliflozin showed no effects on fertility at any of the doses studied.
(2) Sitagliptin: There are no controlled test results in pregnant women, so its use in pregnant women is not recommended.
2) Nursing mothers
(1) Dapagliflozin: It is not known whether dapagliflozin and its metabolites are transferred into human milk. Pharmacodynamic/toxicological data in animals indicate excretion of dapagliflozin/metabolite in milk and pharmacologically mediated effects in nursing offspring. Risk to neonates/infants cannot be excluded. Dapagliflozin should not be used during breastfeeding.
(2) Sitagliptin: Sitagliptin is reported to be secreted into milk and plasma at a ratio of 4:1 in rats, so it is not administered to nursing mothers.
8. Administration to children
The safety and efficacy of dapagliflozin in pediatric patients have not been established.
9. Administration to elderly people
1) Sitagliptin
Of the total subjects (3,884) in the pre-approval clinical trial, 725 were over 65 years of age and 61 were over 75 years of age. Safety and efficacy in elderly patients aged 65 years or older were similar to those in younger patients. Although there was no difference in responsiveness between this patient group and the younger patient group, it cannot be ruled out that susceptibility may be increased in some elderly patients.
Sitagliptin is known to be largely excreted by the kidneys. Elderly people are prone to decreased kidney function, so care must be taken when selecting the dose in the elderly, and it is recommended to periodically evaluate kidney function before and after administration of sitagliptin.
10. Treatment in case of overdose
1) Dapagliflozin
Dapagliflozin did not show any toxicity at single oral doses of up to 500 mg (50 times the maximum recommended human dose) in healthy subjects. These subjects had detectable urinary glucose throughout the treatment period (more than 5 days for the 500 mg dose), no dehydration, hypotension, or electrolyte imbalances were reported, and there were no clinically significant effects on the QTc interval. The incidence of hypoglycemia was similar to placebo. In a clinical trial in which healthy subjects and patients with type 2 diabetes were administered up to 100 mg (10 times the maximum recommended human dose) once daily for 2 weeks, the incidence of hypoglycemia was slightly higher than in the placebo group and was not dose-related. Rates of adverse events, including dehydration or hypotension, were similar to the placebo group, and there were no clinically meaningful dose-related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function.
If overdose occurs, appropriate symptomatic treatment should be administered according to the patient's clinical condition. Elimination of dapagliflozin by dialysis has not been studied.
2) Sitagliptin
In clinical trials of sitagliptin, a single dose of up to 800 mg of sitagliptin was administered to healthy adults. In one study administering 800 mg of sitagliptin, an increase in mean QTc of up to 8.0 msec was observed, but this is not believed to be clinically relevant. There is no experience administering doses exceeding 800 mg in humans.
In case of overdose, general symptomatic treatment is administered (e.g., removal of unabsorbed drug from the gastrointestinal tract and clinical monitoring including electrocardiogram), and auxiliary treatment is provided depending on the patient's condition.
Sitagliptin can be partially removed by dialysis. In clinical trials, approximately 13.5% of the administered dose was removed during hemodialysis over 3 to 4 hours. Long-term hemodialysis should be considered if clinically appropriate. It is not known whether sitagliptin is removed by peritoneal dialysis.
11. Precautions for application
Dapagliflozin has no or little effect on the ability to drive or use machines. Patients should be aware of the risk of hypoglycemia when administering dapagliflozin in combination with sulfonylurea or insulin.
12. Precautions for storage and handling
1) Store out of reach of children.
2) It is not advisable to change the container as it may damage the quality of the product or cause an accident. Store in original container.
13. Information for experts
1) Pharmacological action
This drug is a combination of sitagliptin and dapagliflozin for the purpose of improving blood sugar control. Sitagliptin enhances glucose-mediated insulin secretion by selectively inhibiting dipeptidyl peptidase-4 (DPP-4) (incretin effect). Dapagliflozin is a selective inhibitor of sodium glucose cotransporter-2 (SGLT-2), which inhibits glucose reabsorption in the kidney independent of insulin. For both drugs, the action is regulated by blood glucose levels.
2) Pharmacokinetic information
One biopharmaceutical test was conducted to compare and evaluate the bioavailability of this drug (dapagliflozin bisL-proline/sitagliptin phosphate hydrate combination) with the combined administration of approved drugs (dapagliflozin propanediol hydrate single agent and sitagliptin phosphate hydrate single agent). This drug, which is the test drug, and the reference drug, Farxi Tablet 10 mg (dapagliflozin propanediol hydrate) [AstraZeneca Korea Co., Ltd.] and Januvia Tablet 100 mg (sitagliptin phosphate hydrate) [Korea MSD Co., Ltd.], were administered orally once on an empty stomach to healthy adults in a 2 As a result of measuring sitagliptin, when the comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, demonstrating biological equivalence.
3) Clinical trial information
In a study comparing the additional use of dapagliflozin with placebo in patients with type 2 diabetes who had insufficient glycemic control with sitagliptin alone or sitagliptin and metformin in combination, the dapagliflozin treatment group showed a statistically significant decrease in HbA1c compared to placebo at 24 weeks (Table 5, p<0.0001).
Table 5. Outcomes at Week 24 (LOCFa) in a placebo-controlled study comparing the add-on of dapagliflozin in patients with inadequate glycemic control with sitagliptin (alone or in combination with metformin) - see leaflet -
When dapagliflozin 10mg was administered in combination with sitagliptin, fasting blood sugar levels were statistically significantly reduced compared to placebo.
postprandial blood sugar
When 10 mg of dapagliflozin was added to sitagliptin, a decrease in 2-hour postprandial blood sugar levels was observed at 24 weeks and was maintained until 48 weeks.
4) Toxicity test information
(1) Dapagliflozin
① Carcinogenicity: Dapagliflozin did not induce tumors in mice or rats at any of the doses evaluated in the 2-year carcinogenicity study. The oral doses in mice were 5, 15, and 40 mg/kg/day for males and 2, 10, and 20 mg/kg/day for females, and the oral doses in rats were 0.5, 2, and 10 mg/kg/day for both sexes. The highest dose evaluated in mice corresponded to an AUC exposure multiple of approximately 72 (males) and 105 (female) the human AUC at the maximum recommended human dose (MRHD) of 10 mg per day. The AUC exposure in rats was approximately 131 times (males) and 186 times (females) the human AUC at MRHD.
② Mutagenicity: Dapagliflozin was negative in the Ames mutagenicity test and positive in the in vitro chromosomal abnormality test, but this was true when the concentration was over 100 mg/mL under S9 activity conditions. In particular, dapagliflozin was negative for chromosomal abnormalities in in vivo conditions in micronucleus or DNA repair tests conducted on rats at an exposure equivalent to more than 2,100 times the human exposure in MRHD. These studies support that dapagliflozin does not present a genotoxic risk to humans, given the absence of neoplastic findings in rat and mouse carcinogenicity studies.
③ Reproductive dysfunction: In tests on fertility and early embryo development in rats, 15, 75, or 300/210 mg/kg/day of dapagliflozin was administered to males (300 mg/kg/day dose was reduced to 210 mg/kg/day after 4 days), and 3, 15, or 75 mg/kg/day doses were administered to females. Dapagliflozin did not affect mating, fertility, or early embryonic development in males or females at any dose administered (fold exposure ≤1708 and 998 times the MRHD in males and females). However, at 300/210 mg/kg/day, seminal vesicle and epididymal weight decreased, sperm motility and sperm count decreased, and the number of morphologically abnormal sperm was low.
④ Teratogenicity: Direct administration to young rats during the weaning period and indirect exposure to the drug during the second half of pregnancy and lactation (the period corresponding to the second and third trimesters of pregnancy in relation to human kidney development) are associated with an increase in the severity and incidence of renal pelvis dilatation and tubular dilatation in offspring. In a toxicity test in young animals, when dapagliflozin was administered to young rats on the 21st day of life at doses of 1, 15, or 75 mg/kg/day for up to 90 days, renal pelvis dilatation and tubule dilatation were reported at all doses; Exposure to offspring at the lowest dose was more than 15 times the MRHD. These observations were associated with a dose-related increase in kidney mass and macroscopic renal hypertrophy at all doses. The renal pelvis and tubular dilatation observed in young animals were not completely reversed during a recovery period of approximately 1 month.
⑤ Early developmental disorders: In a separate study on prenatal and postnatal development, maternal rats were administered drugs (1, 15, or 75 mg/kg/day) from the 6th day of pregnancy to the 21st day after birth, and the offspring were exposed indirectly through uterus and breastfeeding. (A separate study was conducted to evaluate the effects of dapagliflozin on milk and offspring.) Increased severity or incidence of renal pelvic dilatation was again observed in adult offspring of dams receiving the dose, albeit only at a dose of 75 mg/kg/day (corresponding to dam and foal dapagliflozin exposures of 1415 and 137 times [human levels in MRHD], respectively). Additional developmental toxicity was limited to dose-related reductions in pup body weight, which were observed at doses above 15 mg/kg/day (pup exposure greater than 29 times [human levels in MRHD]). Maternal toxicity was evident only at 75 mg/kg/day and was limited to a transient decrease in body weight and food consumption at the beginning of administration. The NOAEL for developmental toxicity, 1 mg/kg/day, is approximately 19 times the [human level in MRHD] and corresponds to maternal systemic exposure.
In additional embryo-fetal development studies in rats and rabbits, dapagliflozin was administered at intervals corresponding to key periods of organogenesis in each species. No maternal or developmental toxicity was observed in rabbits at any dose administered (20, 60, or 180 mg/kg/day); 180mg/kg/day corresponds to a systemic exposure of approximately 1191 times the MRHD. In rats, dapagliflozin was not embryonic lethal or teratogenic up to a dose of 75 mg/kg/day (approximately 1441 times the MRHD). Maternal and developmental toxicity was associated at a dose of 150 mg/kg/day (approximately 2344 times [human level in MRHD]). Maternal toxicity includes mortality, abnormal clinical signs, and reduction in body weight and food consumption. Developmental toxicities include embryo-fetal mortality, increased fetal malformations and skeletal dysmorphic events, and reduced fetal weight. The malformations are macrovascular malformation, costal and central spinal fusion, and sternum and central sternal duplication. The variation was mainly reduced ossification.
⑥ Animal toxicology: Most effects observed in major repeated-dose toxicity tests on rats and dogs were judged to be accompanied by pharmacologically mediated increases in urinary glucose, and included weight loss and/or decreased body weight gain rate, increased feed consumption, and increased urine volume due to osmotic diuretics. Dapagliflozin was well tolerated when administered orally to rats at a dose of 25 mg/kg/day (more than 346 times the human exposure at MRHD) for up to 6 months and to dogs at a dose of 120 mg/kg/day (more than 3200 times the human exposure at MRHD) for up to 12 months. In addition, as a result of a single-dose test of dapagliflozin, in both rat and dog toxicity tests, dapagliflozin 3-O-glucuronide metabolites were formed at an exposure level (AUC) equivalent to or higher than the expected human dapagliflozin 3-O-glucuronide exposure after administration of dapagliflozin in MRHD. The most notable nonclinical toxicological findings in rats, increased cancellous bone and tissue mineralization (related to increased serum calcium), were observed only at high exposure multiples (>2100-fold based on human exposure at MRHD). Despite reaching an exposure multiple of more than 3200 times the human exposure at MRHD, there were no dose limitations or target organ toxicities in the 12-month dog study.
(2) Sitagliptin
① Carcinogenicity, mutagenicity, fertility: A carcinogenicity test was conducted on male and female rats at doses of 50, 150, and 500 mg/kg/day of sitagliptin for 2 years. The incidence of combined liver adenoma/carcinoma increased in both sexes, and in females, the incidence of liver cancer increased at 500 mg/kg. This dose is almost 60 times the maximum recommended human dose (MRHD) of 100 mg/day based on AUC comparison. Liver tumors were not observed at 150 mg/kg, which is nearly 20 times the maximum recommended human dose.
A carcinogenicity test was conducted on male and female mice at doses of 50, 125, 250, and 500 mg/kg/day of sitagliptin for 2 years. At 500 mg/kg, which is almost 70 times the maximum recommended human dose, there was no increase in tumor occurrence in any organ. Sitagliptin was not shown to be mutagenic or cause chromosomal abnormalities in a series of genotoxicity studies, such as reverse mutation (Ames) test using bacteria, in vitro chromosomal aberration test and in vitro cytogenetic analysis using CHO cells, in vitro alkaline elution assay in rat liver cells, and in vivo micronucleus test using mouse hematopoietic cells.
In a rat fertility test, doses of 125, 250, and 1000 mg/kg were administered to males for 4 weeks before mating, at the time of mating, and until the end of mating (about 8 weeks in total), and to females, it was orally administered from 2 weeks before mating until the 7th day of pregnancy. No fertility abnormalities were observed at 125 mg/kg (about 12 times the maximum recommended human dose). At high doses (25 and 100 times the maximum recommended human dose), a dose-independent increase in resorption was observed in females.
② Reproductive toxicity: In reproductive toxicity tests conducted in rats and rabbits, there was no damage to fertility or fetuses when sitagliptin was administered at a dose of 125 mg/kg (corresponding to 12 times the maximum recommended human dose). However, there are no controlled test results for pregnant women, and the results of reproductive toxicity tests in animals do not always predict reactions in humans, so use in pregnant women is not recommended.
When sitagliptin was administered to pregnant female rats and rabbits on days 6 to 20 of pregnancy (organ formation period), there were no teratogenic effects when administered at doses up to 250 mg/kg in rats and up to 125 mg/kg in rabbits, or approximately 30 or 20 times the maximum recommended human dose of 100 mg/day based on AUC comparison. When administered orally in rats at a dose of 1000 mg/kg/day (corresponding to approximately 100 times the exposure of 100 mg/day, the maximum recommended dose in humans), the incidence of rib hypoplasia in offspring increased with higher doses.
Body weight decreased in both male and female rat pups that were orally administered at a dose of 1000 mg/kg/day from the 6th day of pregnancy to the 21st day of lactation. No abnormalities in function or behavior were observed.
About 45% of sitagliptin passed through the placenta at 2 hours and 80% at 24 hours after administration to pregnant rats. In rabbits, the rate was approximately 66% at 2 hours and 30% at 24 hours after administration.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
28 tablets/box ((7 tablets/PTP)X4)
7. Period of use
24 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | Dapazin-S duo Tab. 10/100mg | Precautions for use | 2025.08.29 | PDF0130_202301844_Precautions for use (Dapagene S Duo Tablets 10_100mg).pdf |